{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1576,"total_is_capped":false,"direct_labels_cover":3,"predictions_cover":1576,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"38079aa63b5f","filters":{"topic":"HIV/AIDS drug development and treatment"}},"results":[{"id":"W2147458973","doi":"10.1038/nrd4010","title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","year":2013,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institut National de la Recherche Scientifique","funders":"Ligue Contre le Cancer; Olav Raagholt og Gerd Meidel Raagholts stiftelse; Association pour la Recherche sur le Cancer","keywords":"Nucleoside; Medicine; Cancer; Drug development; Nucleoside analogue; Cancer treatment; Cancer therapy; Drug; Computational biology; Pharmacology; Biology; Internal medicine; Genetics","authors":[{"name":"Lars Petter Jordheim","is_ca":true},{"name":"David Durantel","is_ca":false},{"name":"Fabien Zoulim","is_ca":false},{"name":"Charles Dumontet","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02570177930017246,"gpt":0.3578543889485624,"spread":0.3321526096483899,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004634924,0.0005876691,0.002694753,0.000218043,0.000094594,0.00006209892,0.0001934393,0.0002277528,0.00001106821],"category_scores_gemma":[0.000159398,0.0002926014,0.0003889235,0.0002758602,0.000122105,0.0003585061,0.00009123878,0.000463417,0.000005973146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001273935,"about_ca_system_score_gemma":0.0004168886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006101751,"about_ca_topic_score_gemma":0.0001958465,"domain_scores_codex":[0.9976183,0.0001570191,0.001079337,0.0005544879,0.0002816626,0.0003092329],"domain_scores_gemma":[0.9985734,0.0004063704,0.00054263,0.0003275873,0.00004827939,0.0001016863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001607632,0.000118662,0.0006119627,0.04444409,0.0001531755,0.000005616919,0.0004185391,2.153346e-8,2.286967e-7,0.0001991174,0.00258345,0.951449],"study_design_scores_gemma":[0.0004549045,0.00001834963,0.0003721397,0.0350874,0.001553744,0.00001080458,0.0001026392,6.848489e-7,0.000002281599,0.00007295578,0.9620333,0.0002907867],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003736981,0.9941388,0.000005923235,0.0003001735,0.0001184163,0.004712288,0.0001395744,0.00001130901,0.0001998627],"genre_scores_gemma":[0.00006901905,0.9941119,0.002169,0.0001510728,0.0001303448,0.001855496,0.0003949126,0.00004519329,0.001073042],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9594499,"threshold_uncertainty_score":0.9999526,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2122280827","doi":"10.1001/jama.296.7.827","title":"Treatment for Adult HIV Infection","year":2006,"lang":"en","type":"article","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1037,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Antiretroviral therapy; Ritonavir; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Intensive care medicine; MEDLINE; Human immunodeficiency virus (HIV); Family medicine; Immunology; Viral load","authors":[{"name":"Scott M. Hammer","is_ca":false},{"name":"Michael S. Saag","is_ca":false},{"name":"Mauro Schechter","is_ca":false},{"name":"Joan Montaner","is_ca":true},{"name":"Robert T. Schooley","is_ca":false},{"name":"Donna M. Jacobsen","is_ca":false},{"name":"Melanie Thompson","is_ca":false},{"name":"Charles C. J. Carpenter","is_ca":false},{"name":"Margaret A. Fischl","is_ca":false},{"name":"Brian Gazzard","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Martin Hirsch","is_ca":false},{"name":"David Katzenstein","is_ca":false},{"name":"Douglas D. Richman","is_ca":false},{"name":"Stefano Vella","is_ca":false},{"name":"Patrick Yéni","is_ca":false},{"name":"Paul A. Volberding","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01152513169205912,"gpt":0.2615392131010178,"spread":0.2500140814089587,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002180773,0.00009892297,0.0001334702,0.00005743391,0.00005472764,0.00001413863,0.00001086242,0.00005163974,0.00005899672],"category_scores_gemma":[0.0000223173,0.00007021243,0.00008551644,0.00006365258,0.00000980556,0.00004137543,0.000003980073,0.00002259932,0.0002029664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001961682,"about_ca_system_score_gemma":0.00004255394,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001060192,"about_ca_topic_score_gemma":0.00006915796,"domain_scores_codex":[0.9995198,0.000005905986,0.0001189374,0.0001366516,0.00007918897,0.0001395625],"domain_scores_gemma":[0.9996998,0.00002633755,0.00002783137,0.000101307,0.0001027638,0.00004200669],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007110534,0.002124522,0.5339785,0.0001016319,0.0003856332,0.0000967572,0.0005086253,0.00001066012,0.001160884,0.007707241,0.2697666,0.1834479],"study_design_scores_gemma":[0.01887559,0.0005848372,0.1908065,0.00006432147,0.000316923,0.000063808,0.00004064813,0.0004961799,0.02728348,0.0007519675,0.760512,0.0002037457],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9309596,0.00009850605,0.001135238,0.02819597,0.0001894503,0.001102833,0.00002218217,0.0001869651,0.03810919],"genre_scores_gemma":[0.8262647,0.00004203077,0.004078272,0.0002384086,0.0005628162,0.0002950507,0.0003789631,0.00001896003,0.1681208],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4907454,"threshold_uncertainty_score":0.286318,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133315239","doi":"10.1001/jama.283.3.381","title":"Antiretroviral Therapy in Adults","year":2000,"lang":"en","type":"review","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1036,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Interim; Antiretroviral therapy; Intensive care medicine; Clinical trial; Clinical research; Human immunodeficiency virus (HIV); MEDLINE; ANTIRETROVIRAL AGENTS; Alternative medicine; Family medicine; Viral load; Pathology","authors":[{"name":"Charles C. J. Carpenter","is_ca":false},{"name":"David A. Cooper","is_ca":false},{"name":"Margaret A. Fischl","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Brian Gazzard","is_ca":false},{"name":"Scott M. Hammer","is_ca":false},{"name":"Martin Hirsch","is_ca":false},{"name":"Donna M. Jacobsen","is_ca":false},{"name":"David Katzenstein","is_ca":false},{"name":"Joan Montaner","is_ca":true},{"name":"Douglas D. Richman","is_ca":false},{"name":"Michael S. Saag","is_ca":false},{"name":"Mauro Schechter","is_ca":false},{"name":"Robert T. Schooley","is_ca":false},{"name":"Melanie Thompson","is_ca":false},{"name":"Stefano Vella","is_ca":false},{"name":"Patrick Yéni","is_ca":false},{"name":"Paul A. Volberding","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02841402617113739,"gpt":0.3167798492283666,"spread":0.2883658230572292,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009462135,0.0003306184,0.001317745,0.000280501,0.00002052667,0.00001862058,0.00009652416,0.0002891577,0.0006830911],"category_scores_gemma":[0.00001534421,0.0002159186,0.0003112189,0.0003337079,0.00002241182,0.00004308581,0.00001543887,0.0003344533,0.001098591],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001658075,"about_ca_system_score_gemma":0.0003005332,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001951305,"about_ca_topic_score_gemma":0.00000537244,"domain_scores_codex":[0.998726,0.00005867195,0.000418539,0.0003286215,0.0002054753,0.0002627468],"domain_scores_gemma":[0.999484,0.00004429435,0.00008677061,0.0002842387,0.00001734936,0.00008337195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006720195,0.0001677366,0.000488313,0.002560164,0.0001181683,0.0004043127,0.0001364641,3.177683e-9,6.841677e-9,0.000009904543,0.00434443,0.9917033],"study_design_scores_gemma":[0.00261608,0.0001540998,0.0002080431,0.02241154,0.000117628,0.00005480408,0.000005709642,6.139389e-7,5.575654e-7,0.000004213962,0.9742394,0.0001873051],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003384483,0.9822692,1.087991e-7,0.0002261709,0.00008484677,0.000913026,0.00001273869,0.00004640553,0.01610904],"genre_scores_gemma":[0.00003277848,0.9679391,0.0001525153,0.0001014966,0.0002586024,0.0001107189,0.00036969,0.00004574458,0.0309893],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.991516,"threshold_uncertainty_score":0.9996791,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2109046728","doi":"10.1371/journal.pone.0004724","title":"Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update","year":2009,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":960,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Drug resistance; HIV drug resistance; Resistance mutation; Drug; Mutation; Virology; Medicine; Resistance (ecology); Human immunodeficiency virus (HIV); Biology; Genetics; Pharmacology; Antiretroviral therapy; Gene; Viral load; Reverse transcriptase; Polymerase chain reaction","authors":[{"name":"Diane Bennett","is_ca":false},{"name":"Ricardo Camacho","is_ca":false},{"name":"Dan Oţelea","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Hervé Fleury","is_ca":false},{"name":"Mark Kiuchi","is_ca":false},{"name":"Walid Heneine","is_ca":false},{"name":"Rami Kantor","is_ca":false},{"name":"Michael R. Jordan","is_ca":false},{"name":"Jonathan Schapiro","is_ca":false},{"name":"Anne‐Mieke Vandamme","is_ca":false},{"name":"Paul Sandstrom","is_ca":true},{"name":"Charles A. Boucher","is_ca":false},{"name":"David van de Vijver","is_ca":false},{"name":"Soo‐Yon Rhee","is_ca":false},{"name":"Tommy F. Liu","is_ca":false},{"name":"Deenan Pillay","is_ca":false},{"name":"Robert W. Shafer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0173285574361156,"gpt":0.2399108085780483,"spread":0.2225822511419327,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002052582,0.0002073871,0.0005424905,0.0001297576,0.0001065627,0.00001172774,0.000108361,0.00005098844,0.00009658455],"category_scores_gemma":[0.00007873615,0.0001909768,0.0001175287,0.0003491385,0.0000617804,0.00007494196,0.000005283958,0.0001004536,0.00005860302],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007887703,"about_ca_system_score_gemma":0.0001270717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001436813,"about_ca_topic_score_gemma":0.0002021836,"domain_scores_codex":[0.9984396,0.00003947723,0.0004558005,0.0003251451,0.0004180624,0.0003219809],"domain_scores_gemma":[0.9989746,0.0001387979,0.0001421024,0.0003333905,0.0002827562,0.0001283512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.009266855,0.03018562,0.05081337,0.005098167,0.005895502,0.0002622723,0.01456651,0.00001495552,0.052116,0.01035484,0.8177819,0.003644035],"study_design_scores_gemma":[0.04489246,0.0002965214,0.1533625,0.00674,0.003859078,0.000007684345,0.0009061124,0.0005448543,0.580257,0.01617295,0.190381,0.002579827],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8535334,0.004712563,0.00135,0.1240703,0.00005787444,0.002858935,0.0005857877,0.0002985146,0.01253254],"genre_scores_gemma":[0.7136631,0.0002961522,0.04148069,0.0003373914,0.000070758,0.0001133061,0.0006040093,0.00003067576,0.2434039],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6274009,"threshold_uncertainty_score":0.7787808,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133649749","doi":"10.1056/nejmoa035026","title":"Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America","year":2003,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":915,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Toronto; St. Paul's Hospital; University of British Columbia","funders":"Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Enfuvirtide; Regimen; Medicine; Viral load; Internal medicine; Liter; Virology; Randomization; Drug resistance; Dolutegravir; Human immunodeficiency virus (HIV); Randomized controlled trial; Immunology; Gastroenterology; Antiretroviral therapy; Biology; Gp41; Microbiology","authors":[{"name":"Jacob Lalezari","is_ca":false},{"name":"Keith Henry","is_ca":false},{"name":"Mary O’Hearn","is_ca":false},{"name":"Joan Montaner","is_ca":true},{"name":"Peter J. Piliero","is_ca":false},{"name":"Benoît Trottier","is_ca":false},{"name":"Sharon Walmsley","is_ca":true},{"name":"Calvin Cohen","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Joseph J. Eron","is_ca":false},{"name":"Jain Chung","is_ca":false},{"name":"Ralph DeMasi","is_ca":false},{"name":"Lucille Donatacci","is_ca":false},{"name":"Claude Drobnes","is_ca":false},{"name":"John Delehanty","is_ca":false},{"name":"Miklos Salgo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01274361375654826,"gpt":0.2547374387986145,"spread":0.2419938250420663,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005117994,0.0001805738,0.0005134963,0.0003737545,0.00006335629,0.000008945173,0.00003447577,0.0000458905,0.00006954792],"category_scores_gemma":[0.0003612177,0.0001155738,0.00005213144,0.0002595441,0.00006306687,0.0001112092,0.00000820479,0.0002231628,0.000003508049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009387914,"about_ca_system_score_gemma":0.0001999428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004242666,"about_ca_topic_score_gemma":0.0003523676,"domain_scores_codex":[0.9986228,0.00009212975,0.0005876838,0.0001689689,0.0003150511,0.0002133827],"domain_scores_gemma":[0.9989992,0.000127742,0.0002668288,0.0001116332,0.0001324353,0.0003621574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003022275,0.0003756815,0.9011937,0.0001131967,0.0001419227,0.0003573283,0.01240041,0.00002612407,0.002409268,0.0000923667,0.013293,0.06657468],"study_design_scores_gemma":[0.1873111,0.0044864,0.3828684,0.001369132,0.0007396122,0.001033106,0.002045126,0.000162393,0.001803461,0.0004240324,0.4173515,0.000405733],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918988,0.0007627833,0.0009580255,0.005325241,0.0002570626,0.000300223,0.000003461111,0.00001175605,0.0004825993],"genre_scores_gemma":[0.9931716,0.0006359919,0.002798583,0.0002395724,0.00105976,0.000005101692,0.00003226006,0.00002024907,0.002036921],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5183253,"threshold_uncertainty_score":0.4712962,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2094241860","doi":"10.1056/nejmoa1215541","title":"Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":878,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"","keywords":"Dolutegravir; Abacavir; Medicine; Lamivudine; Virology; Integrase inhibitor; Regimen; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus; Internal medicine; Viral load; Hepatitis B virus","authors":[{"name":"Sharon Walmsley","is_ca":true},{"name":"Antonio Antela","is_ca":false},{"name":"Nathan Clumeck","is_ca":false},{"name":"Dan Duiculescu","is_ca":false},{"name":"Andrea Eberhard","is_ca":false},{"name":"Félix Gutiérrez","is_ca":false},{"name":"Laurent Hocqueloux","is_ca":false},{"name":"Franco Maggiolo","is_ca":false},{"name":"Uriel Sandkovsky","is_ca":false},{"name":"Catherine Granier","is_ca":false},{"name":"Keith A. Pappa","is_ca":false},{"name":"Brian Wynne","is_ca":false},{"name":"Sherene Min","is_ca":false},{"name":"Garrett Nichols","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02589605435681262,"gpt":0.2881361588825451,"spread":0.2622401045257324,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003370672,0.0001856239,0.0006005288,0.0001872249,0.00006520598,0.000006628833,0.00006477439,0.00005667518,0.0003072844],"category_scores_gemma":[0.0001296303,0.00008122395,0.0001683647,0.0001593411,0.00008949399,0.00007620741,0.000005853964,0.000112404,0.00001753997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001836069,"about_ca_system_score_gemma":0.0002093689,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002399114,"about_ca_topic_score_gemma":0.00004002747,"domain_scores_codex":[0.9987256,0.00003419068,0.0005956219,0.0001062377,0.0003530311,0.0001853513],"domain_scores_gemma":[0.9985293,0.0004408484,0.0003492776,0.0001698956,0.0003035252,0.0002071107],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001987146,0.0006980037,0.03803532,0.00009480541,0.001688799,0.00007346356,0.006179759,0.00006433878,0.002933756,0.0002582408,0.07238622,0.8756002],"study_design_scores_gemma":[0.1698557,0.009801763,0.08845765,0.0006456648,0.00220328,0.001144846,0.0005408712,0.0004555273,0.002904985,0.0007818942,0.7230367,0.0001710691],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8732094,0.007626095,0.007280442,0.1060672,0.001456992,0.001915071,0.000007587825,0.00002752765,0.002409668],"genre_scores_gemma":[0.9668818,0.006025749,0.002202048,0.0001989313,0.004450582,0.00003447578,0.00002967448,0.00002633631,0.02015039],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8754291,"threshold_uncertainty_score":0.3364549,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099697190","doi":"10.1001/jama.283.18.2417","title":"Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":783,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Drug resistance; Intensive care medicine; Human immunodeficiency virus (HIV); HIV drug resistance; Antiretroviral therapy; MEDLINE; Viral load; Immunology","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02896580900075403,"gpt":0.2595900500640946,"spread":0.2306242410633406,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002305385,0.0001134108,0.0001820479,0.0001059498,0.00005724438,0.0000171815,0.00007080127,0.00004414024,0.0002140882],"category_scores_gemma":[0.0001105312,0.000107463,0.0000663804,0.0003811881,0.00004222685,0.0002424654,0.0000161107,0.0001281272,0.0000322778],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001793267,"about_ca_system_score_gemma":0.00004986771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007063152,"about_ca_topic_score_gemma":0.0001700046,"domain_scores_codex":[0.9989859,0.00003684358,0.0003275526,0.0002210791,0.0002071435,0.0002214736],"domain_scores_gemma":[0.9995098,0.000063375,0.00007594717,0.0001572351,0.0001096574,0.00008400092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00008505762,0.0004122518,0.7422323,0.00003243114,0.00008533265,0.00001348499,0.0008277699,0.000005382732,0.00001536656,0.0001261984,0.004759085,0.2514054],"study_design_scores_gemma":[0.002399022,0.00002361359,0.9695877,0.00009969655,0.00004371234,0.00001198873,0.0001180583,0.0001781423,0.0005944009,0.00007214204,0.02673312,0.0001383571],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9647372,0.00001645478,0.00001079783,0.005653333,0.0001336906,0.0004146977,0.00001734324,0.00005161139,0.02896482],"genre_scores_gemma":[0.9110479,0.00009506236,0.008408638,0.0001590672,0.0001147394,0.0003784968,0.0001544228,0.00001346121,0.07962818],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.251267,"threshold_uncertainty_score":0.4382212,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052991207","doi":"10.1056/nejmoa012354","title":"Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital; University of Toronto; University Health Network","funders":"","keywords":"Lopinavir; Lopinavir/ritonavir; Ritonavir; Nelfinavir; Medicine; Virology; Protease inhibitor (pharmacology); Human immunodeficiency virus (HIV); Pharmacology; Viral load; Antiretroviral therapy","authors":[{"name":"Sharon Walmsley","is_ca":true},{"name":"Barry Bernstein","is_ca":false},{"name":"Martin King","is_ca":false},{"name":"José Ramón Arribas","is_ca":false},{"name":"Gildon Beall","is_ca":false},{"name":"Peter Ruane","is_ca":false},{"name":"Margaret Johnson","is_ca":false},{"name":"David W. Johnson","is_ca":false},{"name":"Richard Lalonde","is_ca":true},{"name":"Anthony J. Japour","is_ca":false},{"name":"Scott Brun","is_ca":false},{"name":"Eugene Sun","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08347689925760145,"gpt":0.3403015943720378,"spread":0.2568246951144364,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003102544,0.0001837421,0.0005298631,0.0001697614,0.00008028023,0.000005270331,0.00006534622,0.00006309317,0.000366518],"category_scores_gemma":[0.0003053399,0.00009131808,0.0001704185,0.0001709921,0.0001043906,0.00006755537,0.00000745333,0.0001253106,0.00001044972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001676034,"about_ca_system_score_gemma":0.0001444715,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005689509,"about_ca_topic_score_gemma":0.00002594923,"domain_scores_codex":[0.9986967,0.00004270961,0.0005576193,0.0001113306,0.0003909007,0.0002007361],"domain_scores_gemma":[0.9984675,0.0006082374,0.0003128919,0.000163756,0.0002004996,0.0002470902],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007567605,0.0009514604,0.01701804,0.00007403263,0.001438198,0.0002795268,0.005946808,0.00003501836,0.0005159377,0.0002426547,0.05753129,0.9083995],"study_design_scores_gemma":[0.1997792,0.01230287,0.00762713,0.0004513562,0.001845086,0.000919254,0.0002576646,0.0002512751,0.002065436,0.0001427933,0.7742292,0.0001287245],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8009954,0.01465664,0.004024142,0.1664637,0.005099353,0.001665572,0.0000182413,0.00004612749,0.00703079],"genre_scores_gemma":[0.9793385,0.005618116,0.0009617336,0.0001615229,0.006236184,0.00001369737,0.00002072914,0.00002487982,0.007624684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9082707,"threshold_uncertainty_score":0.4013115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009494891","doi":"10.1056/nejmoa1904398","title":"Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; ViiV Healthcare","keywords":"Rilpivirine; Medicine; Confidence interval; Liter; Clinical endpoint; Internal medicine; Reverse-transcriptase inhibitor; Human immunodeficiency virus (HIV); Integrase inhibitor; Pharmacotherapy; Viral load; Randomized controlled trial; Antiretroviral therapy; Virology","authors":[{"name":"Susan Swindells","is_ca":false},{"name":"Jaime Andrade‐Villanueva","is_ca":false},{"name":"Gary Richmond","is_ca":false},{"name":"Giuliano Rizzardini","is_ca":false},{"name":"Axel Baumgarten","is_ca":false},{"name":"Mar Masiá","is_ca":false},{"name":"Gulam Latiff","is_ca":false},{"name":"Vadim Pokrovsky","is_ca":false},{"name":"Fritz Bredeek","is_ca":false},{"name":"Graham Smith","is_ca":false},{"name":"Pedro Cahn","is_ca":false},{"name":"Kim Ys","is_ca":false},{"name":"Susan L. Ford","is_ca":false},{"name":"Christine L. Talarico","is_ca":false},{"name":"Parul Patel","is_ca":false},{"name":"Vasiliki Chounta","is_ca":false},{"name":"Herta Crauwels","is_ca":false},{"name":"Wim Parys","is_ca":false},{"name":"Simon Vanveggel","is_ca":false},{"name":"Joseph Mrus","is_ca":false},{"name":"Jenny Huang","is_ca":true},{"name":"Conn Harrington","is_ca":false},{"name":"Krischan J Hudson","is_ca":false},{"name":"David A. Margolis","is_ca":false},{"name":"Kimberly Y. Smith","is_ca":false},{"name":"Peter Williams","is_ca":false},{"name":"William Spreen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02603651210254818,"gpt":0.2850169726029176,"spread":0.2589804605003694,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003827214,0.0001369937,0.0005784279,0.00009160642,0.00003237251,0.000003427639,0.00005936014,0.00004246953,0.00009199258],"category_scores_gemma":[0.0006654186,0.00007822465,0.0000629764,0.0001099709,0.00006716722,0.00006236428,0.00001869429,0.000183977,0.000001280513],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002343211,"about_ca_system_score_gemma":0.0001179844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008153505,"about_ca_topic_score_gemma":0.000004141058,"domain_scores_codex":[0.9988943,0.0000266728,0.0005112416,0.000119593,0.0002923535,0.0001558293],"domain_scores_gemma":[0.998834,0.0002204519,0.0003298935,0.00007566546,0.0001794412,0.0003605835],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01186546,0.0002459835,0.2230913,0.001044958,0.0008100944,0.001142634,0.0141965,0.00002423981,0.03903775,0.0002173344,0.1491315,0.5591923],"study_design_scores_gemma":[0.3327036,0.008752234,0.06128334,0.007047366,0.001892085,0.003248676,0.002557265,0.0009886075,0.03038643,0.000628491,0.5500757,0.0004362205],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.778251,0.003696359,0.01691831,0.1988108,0.0004451473,0.0005339184,0.00001143427,0.0000200471,0.001312972],"genre_scores_gemma":[0.9891814,0.000551135,0.005870401,0.0004698965,0.001783472,0.000001275834,0.00001383954,0.00001672529,0.002111834],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5587561,"threshold_uncertainty_score":0.3189909,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162761942","doi":"10.1086/655681","title":"Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients","year":2010,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":558,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Renal function; Nephrotoxicity; Cochrane Library; Confidence interval; Meta-analysis; Internal medicine; Randomized controlled trial; Hypophosphatemia; Creatinine; Adverse effect; Relative risk; Kidney","authors":[{"name":"Ryan Cooper","is_ca":true},{"name":"Natasha Wiebe","is_ca":true},{"name":"Nathaniel Smith","is_ca":false},{"name":"Philip Keiser","is_ca":false},{"name":"Saraladevi Naicker","is_ca":false},{"name":"Marcello Tonelli","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04352254162317223,"gpt":0.3787250113462425,"spread":0.3352024697230703,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009014785,0.000766258,0.0144106,0.0005735765,0.00006829412,0.00002531972,0.0001665619,0.0004612479,0.0002998133],"category_scores_gemma":[0.002404223,0.0004564488,0.00415045,0.001392665,0.0002430583,0.00008127355,0.0001498707,0.000722497,0.00009699354],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001084323,"about_ca_system_score_gemma":0.0004597089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007783537,"about_ca_topic_score_gemma":0.00005443732,"domain_scores_codex":[0.993313,0.001129053,0.00397462,0.0008289599,0.0004054451,0.00034891],"domain_scores_gemma":[0.9950623,0.001568914,0.001703831,0.0009080892,0.0002807984,0.0004761001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00001978646,0.002807221,0.02826482,0.7932116,0.1691262,0.00004424615,0.000009361012,1.229686e-7,3.242903e-9,0.00002220857,0.0002511355,0.006243344],"study_design_scores_gemma":[0.001202018,0.0001686661,0.004139154,0.08121481,0.8983936,0.000006804145,0.000001201662,0.000001715483,2.531001e-8,0.00001717662,0.01447172,0.0003831026],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000663557,0.993397,0.000007656731,0.00008009507,0.00007569508,0.0055692,0.0004423318,0.00008251874,0.0002791526],"genre_scores_gemma":[0.0002292049,0.9956994,0.00002335719,0.0001847174,0.00003887466,0.000997719,0.001460565,0.00005794395,0.001308206],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7292675,"threshold_uncertainty_score":0.9997887,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139430929","doi":"10.1016/s0140-6736(12)61853-4","title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":546,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada); Sunnybrook Health Science Centre; Health Sciences Centre","funders":"ViiV Healthcare","keywords":"Dolutegravir; Raltegravir; Medicine; Emtricitabine; Integrase inhibitor; Abacavir; Lamivudine; Adverse effect; Clinical endpoint; Virology; Internal medicine; Efavirenz; Clinical trial; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","authors":[{"name":"François Raffi","is_ca":false},{"name":"Anita Rachlis","is_ca":true},{"name":"Hans‐Jürgen Stellbrink","is_ca":false},{"name":"W. D. Hardy","is_ca":false},{"name":"Carlo Torti","is_ca":false},{"name":"Chloe Orkin","is_ca":false},{"name":"Mark Bloch","is_ca":false},{"name":"Daniel Podzamczer","is_ca":false},{"name":"Vadim Pokrovsky","is_ca":false},{"name":"Federico Pulido","is_ca":false},{"name":"Steve Almond","is_ca":true},{"name":"David M. Margolis","is_ca":false},{"name":"Clare Brennan","is_ca":false},{"name":"Sherene Min","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03887473312597239,"gpt":0.28644908395491,"spread":0.2475743508289376,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006588555,0.0003987231,0.0008577756,0.00008972549,0.0002553745,0.0001265033,0.0003511779,0.00009902829,0.00009376642],"category_scores_gemma":[0.00008978076,0.0001923611,0.0001164114,0.0005211277,0.0001605442,0.0002061225,0.0001089301,0.0006368615,0.0008263007],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00019179,"about_ca_system_score_gemma":0.0001733351,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01303532,"about_ca_topic_score_gemma":0.004393389,"domain_scores_codex":[0.997694,0.0002082345,0.0005215004,0.0005327255,0.0005136925,0.0005298894],"domain_scores_gemma":[0.998049,0.0004014799,0.0002158369,0.001080062,0.0001279798,0.0001256613],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3139771,0.0008699053,0.6629937,0.00002059087,0.0004876085,0.0001155142,0.008170934,0.00002107381,0.00003779811,0.00001905906,0.01136417,0.001922575],"study_design_scores_gemma":[0.3992863,0.0006747048,0.5941631,0.0002473042,0.0002545517,0.000005265117,0.001629777,0.0001052349,0.0001245617,0.00002251702,0.003242869,0.0002438199],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823872,0.0001018746,0.00001693021,0.008264402,0.0003541893,0.004255499,0.00004467352,0.0001098511,0.004465315],"genre_scores_gemma":[0.9948275,0.0001807764,0.0003514788,0.0002273463,0.0009514319,0.0005369217,0.0001273005,0.00003628994,0.002760959],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08530919,"threshold_uncertainty_score":0.9999517,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2021877795","doi":"10.1086/375597","title":"Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel","year":2003,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":516,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"U.S. Food and Drug Administration; International AIDS Society","keywords":"Medicine; Drug resistance; HIV drug resistance; Antiretroviral drug; Human immunodeficiency virus (HIV); Intensive care medicine; Immunology; Antiretroviral therapy; Virology; Family medicine; Viral load; Biology","authors":[{"name":"Martin Hirsch","is_ca":false},{"name":"Françoise Brun‐Vézinet","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"Brian Conway","is_ca":true},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Richard T. D’Aquila","is_ca":false},{"name":"Lisa M. Demeter","is_ca":false},{"name":"Scott M. Hammer","is_ca":false},{"name":"Victoria A. Johnson","is_ca":false},{"name":"Clive Loveday","is_ca":false},{"name":"John W. Mellors","is_ca":false},{"name":"Donna M. Jacobsen","is_ca":false},{"name":"Douglas D. Richman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04452468622132792,"gpt":0.3519511573071248,"spread":0.3074264710857969,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003071164,0.0002016013,0.0004078403,0.0001313532,0.0001429433,0.00002579482,0.00009952343,0.00008153042,0.0001512035],"category_scores_gemma":[0.001628144,0.0001690055,0.0001116979,0.0009821821,0.0002067028,0.0002145053,0.00002969646,0.0002484971,0.00002383756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001325907,"about_ca_system_score_gemma":0.0004092506,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008541222,"about_ca_topic_score_gemma":0.000295922,"domain_scores_codex":[0.9981997,0.0001825566,0.0007314503,0.0003974633,0.0002422006,0.0002466192],"domain_scores_gemma":[0.9984554,0.0002970592,0.0002573869,0.0003070552,0.0005289244,0.0001541974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001497986,0.003414791,0.992654,0.0000517459,0.0001464402,0.00002561404,0.000200115,0.000005998378,0.0000882048,0.0004646438,0.0006940472,0.002104643],"study_design_scores_gemma":[0.006043704,0.001099534,0.9892676,0.0006330522,0.0001946536,0.000007699388,0.0001978135,0.00009768156,0.0001831265,0.0001944209,0.001809593,0.0002711101],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925268,0.0001414699,0.00002368621,0.00009706221,0.0002543019,0.0003761092,0.00003390634,0.00009155528,0.006455122],"genre_scores_gemma":[0.995505,0.0001492271,0.001604962,0.0001253767,0.00005012589,0.00003513891,0.0002314645,0.00002530526,0.002273366],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005893905,"threshold_uncertainty_score":0.6891842,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2738541296","doi":"10.1016/s0140-6736(17)31917-7","title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":504,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada); Ottawa Hospital","funders":"Bristol-Myers Squibb","keywords":"Rilpivirine; Abacavir; Medicine; Lamivudine; Tolerability; Emtricitabine; Dosing; Internal medicine; Pharmacology; Adverse effect; Viral load; Virology; Human immunodeficiency virus (HIV)","authors":[{"name":"David A. Margolis","is_ca":false},{"name":"Juan González‐García","is_ca":false},{"name":"Hans-Jürgen Stellbrink","is_ca":false},{"name":"Joseph J. Eron","is_ca":false},{"name":"Yazdan Yazdanpanah","is_ca":false},{"name":"Daniel Podzamczer","is_ca":false},{"name":"Thomas A. Lutz","is_ca":false},{"name":"Jonathan B. Angel","is_ca":true},{"name":"Gary Richmond","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"Félix Gutiérrez","is_ca":false},{"name":"Louis Sloan","is_ca":false},{"name":"Marty St. Clair","is_ca":false},{"name":"Miranda Murray","is_ca":false},{"name":"Susan L. Ford","is_ca":false},{"name":"Joseph Mrus","is_ca":false},{"name":"Parul Patel","is_ca":false},{"name":"Herta Crauwels","is_ca":false},{"name":"Sandy Griffith","is_ca":false},{"name":"Kenneth Sutton","is_ca":false},{"name":"David Dorey","is_ca":true},{"name":"Kimberly Y. Smith","is_ca":false},{"name":"Peter Williams","is_ca":false},{"name":"William Spreen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04306374395930505,"gpt":0.3384009476299573,"spread":0.2953372036706522,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001069631,0.0002120583,0.0008416797,0.00007240786,0.0002232144,0.00009989959,0.0002119245,0.00007272747,0.00001305178],"category_scores_gemma":[0.0003236546,0.0001260663,0.00003559738,0.0001096817,0.00015174,0.0002157304,0.0001294169,0.0002681939,0.00000860176],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005726747,"about_ca_system_score_gemma":0.0001137251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001172329,"about_ca_topic_score_gemma":0.001297678,"domain_scores_codex":[0.998695,0.00009924948,0.0004058035,0.0003075472,0.0002147079,0.0002776785],"domain_scores_gemma":[0.9986315,0.0001328463,0.000352013,0.0007276412,0.00006950385,0.00008647907],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8831934,0.00226687,0.07377625,0.0002752734,0.0004156103,0.0003274592,0.002641022,0.000003837921,0.0004642998,0.00002460924,0.001020272,0.03559105],"study_design_scores_gemma":[0.9172025,0.001373475,0.07660567,0.0009519946,0.000208047,0.00003841289,0.00008210133,0.0003414893,0.001459233,0.00002523659,0.001528281,0.0001836023],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911796,0.00005795633,0.00009517209,0.003701448,0.0001046384,0.002289188,0.00003037859,0.00002289655,0.002518659],"genre_scores_gemma":[0.9975559,0.0002451992,0.0007652918,0.00005473284,0.0003659149,0.0001209136,0.00007029696,0.00001890301,0.0008029106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03540745,"threshold_uncertainty_score":0.5140836,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2047734031","doi":"10.1086/427192","title":"Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy","year":2005,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Drug resistance; Internal medicine; Medicine; Hazard ratio; Viral load; Proportional hazards model; Cohort; Resistance mutation; Cohort study; Immunology; Virology; Human immunodeficiency virus (HIV); Reverse transcriptase; Confidence interval; Biology; Polymerase chain reaction; Genetics","authors":[{"name":"P. Richard Harrigan","is_ca":true},{"name":"Robert S. Hogg","is_ca":true},{"name":"Winnie Dong","is_ca":true},{"name":"Benita Yip","is_ca":true},{"name":"Brian Wynhoven","is_ca":true},{"name":"Justin Woodward","is_ca":true},{"name":"Chanson J. Brumme","is_ca":true},{"name":"Zabrina L. Brumme","is_ca":true},{"name":"Theresa Mo","is_ca":true},{"name":"Chris Alexander","is_ca":true},{"name":"Julio Montaner","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007131593421158709,"gpt":0.2540523036130282,"spread":0.2469207101918695,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004501784,0.0001800564,0.0004596866,0.0003317033,0.0001298666,0.00001584477,0.0001126715,0.00003879306,0.00008836773],"category_scores_gemma":[0.0002432976,0.0001170599,0.0001996899,0.0004432633,0.000103222,0.0002424092,0.00002079868,0.000218642,0.000008624836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001949112,"about_ca_system_score_gemma":0.0003243297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000112933,"about_ca_topic_score_gemma":0.00004255606,"domain_scores_codex":[0.998341,0.0001783861,0.0006919684,0.0001089992,0.0004293066,0.0002504034],"domain_scores_gemma":[0.9987245,0.0002370213,0.0005344668,0.000166176,0.0002169795,0.0001208361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004783292,0.001039866,0.9923461,0.00003381773,0.0004090504,0.00004816963,0.002299937,0.0000506186,0.000219636,0.00003789413,0.002369882,0.0006666681],"study_design_scores_gemma":[0.00981667,0.0004782048,0.9836779,0.0004434758,0.0006441647,0.00008505754,0.0009497973,0.0001281341,0.00236461,0.0001214939,0.001109848,0.0001806082],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948846,0.002424798,0.00008816087,0.0007383315,0.0001254008,0.0003940653,0.00004724637,0.00002799847,0.001269362],"genre_scores_gemma":[0.9971397,0.0009618649,0.000120352,0.0001308179,0.0002085688,0.00001001226,0.000021608,0.00002170705,0.0013854],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009338341,"threshold_uncertainty_score":0.4773564,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099826019","doi":"10.1016/s0140-6736(11)60936-7","title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"International AIDS Society","keywords":"Rilpivirine; Emtricitabine; Efavirenz; Medicine; Viral load; Internal medicine; Regimen; Reverse-transcriptase inhibitor; Virology; Pharmacology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"Jean‐Michel Molina","is_ca":false},{"name":"Pedro Cahn","is_ca":false},{"name":"Beatriz Grinsztejn","is_ca":false},{"name":"Adriano Lazzarin","is_ca":false},{"name":"Anthony Mills","is_ca":false},{"name":"Michael S. Saag","is_ca":false},{"name":"Khuanchai Supparatpinyo","is_ca":false},{"name":"Sharon Walmsley","is_ca":true},{"name":"Herta Crauwels","is_ca":false},{"name":"L Rimsky","is_ca":false},{"name":"Simon Vanveggel","is_ca":false},{"name":"Katia Boven","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04770636682178646,"gpt":0.2973200934542903,"spread":0.2496137266325038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002319108,0.0004074871,0.001375711,0.0002143702,0.0001008483,0.00002433323,0.0001074762,0.00008157972,0.0001395129],"category_scores_gemma":[0.00005074505,0.0001872731,0.00008264666,0.0004265694,0.0001423769,0.000121173,0.00002581807,0.0002010703,0.00003214587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001789537,"about_ca_system_score_gemma":0.0002459815,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001470627,"about_ca_topic_score_gemma":0.0003915778,"domain_scores_codex":[0.9984156,0.0001273209,0.0003520634,0.0004027548,0.0002562103,0.0004460006],"domain_scores_gemma":[0.9988072,0.0003291304,0.0001927476,0.0004404851,0.00007993884,0.0001504779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9814925,0.002216834,0.005314439,0.00001937132,0.001496028,0.0002961685,0.004827822,9.287592e-7,0.00006442307,0.00002128442,0.0001287012,0.004121461],"study_design_scores_gemma":[0.9850644,0.00726831,0.004011121,0.0001517355,0.001074572,0.00003448331,0.0002541348,0.0000710157,0.001453648,0.00001027563,0.0003683144,0.0002379742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816163,0.00012452,0.00001830767,0.001103602,0.00006853828,0.007016103,0.00002524371,0.00009475607,0.009932601],"genre_scores_gemma":[0.9941392,0.00014956,0.0005907067,0.0000564788,0.0003165981,0.001538291,0.0001266573,0.000039254,0.003043267],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01252286,"threshold_uncertainty_score":0.7636777,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2032847961","doi":"10.1371/journal.pmed.0050158","title":"Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy","year":2008,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Public Health Agency of Canada","funders":"Centers for Disease Control and Prevention","keywords":"Drug resistance; Resistance mutation; HIV drug resistance; Genotyping; Drug; Virology; Reverse transcriptase; Genotype; Medicine; Viral load; Biology; Genetics; Virus; Pharmacology; Polymerase chain reaction; Antiretroviral therapy; Gene","authors":[{"name":"Jeffrey A. Johnson","is_ca":false},{"name":"LI Jin-fen","is_ca":false},{"name":"Xierong Wei","is_ca":false},{"name":"Jonathan Lipscomb","is_ca":false},{"name":"David M. Irlbeck","is_ca":false},{"name":"Charles Craig","is_ca":false},{"name":"Amanda Smith","is_ca":false},{"name":"Diane Bennett","is_ca":false},{"name":"Michael Monsour","is_ca":false},{"name":"Paul Sandstrom","is_ca":true},{"name":"E. Randall Lanier","is_ca":false},{"name":"Walid Heneine","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05074698755939865,"gpt":0.2885208412925289,"spread":0.2377738537331303,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007422328,0.0003785097,0.0007726194,0.0003024403,0.0002625979,0.000008904957,0.00005122869,0.00007318957,0.0000683161],"category_scores_gemma":[0.0001083824,0.0002451588,0.00006424788,0.0003883177,0.000241661,0.0001005603,0.00001527723,0.0001214782,0.00002614993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008329041,"about_ca_system_score_gemma":0.0001892112,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003003084,"about_ca_topic_score_gemma":0.001811113,"domain_scores_codex":[0.9980971,0.00008987031,0.000454725,0.000507273,0.0004527861,0.0003982252],"domain_scores_gemma":[0.998921,0.0001769241,0.0001926993,0.0003371617,0.00009941815,0.0002728277],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007353742,0.003039154,0.9769949,0.00006256649,0.0006223912,0.001820562,0.01141558,0.000007954784,0.0003205985,0.0000372588,0.003786225,0.001157385],"study_design_scores_gemma":[0.02237922,0.0008149604,0.9672076,0.0007621259,0.001125367,0.00009098621,0.0010154,0.0001556817,0.001999966,0.00004449833,0.004063484,0.0003407105],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710128,0.001462679,0.000004606889,0.02290661,0.00005459255,0.001279259,0.00003667976,0.0001019623,0.003140817],"genre_scores_gemma":[0.9028018,0.0006022126,0.001303369,0.00004962711,0.0001924303,0.0001861556,0.0004634928,0.00002978865,0.09437109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09123027,"threshold_uncertainty_score":0.9997284,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1990925084","doi":"10.1016/s1473-3099(13)70257-3","title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Raltegravir; Dolutegravir; Medicine; Emtricitabine; Tolerability; Abacavir; Lamivudine; Population; Internal medicine; Clinical trial; Integrase inhibitor; Human immunodeficiency virus (HIV); Viral load; Adverse effect; Antiretroviral therapy; Virology; Virus; Chronic hepatitis","authors":[{"name":"François Raffi","is_ca":false},{"name":"Hans Jaeger","is_ca":false},{"name":"Eugenia Quirós-Roldán","is_ca":false},{"name":"Helmut Albrecht","is_ca":false},{"name":"Elena Belonosova","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Jean-Guy Baril","is_ca":false},{"name":"Peré Domingo","is_ca":false},{"name":"Clare Brennan","is_ca":false},{"name":"Steve Almond","is_ca":true},{"name":"Sherene Min","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03039458746160299,"gpt":0.2889750520106316,"spread":0.2585804645490286,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004595702,0.0007033093,0.001398527,0.000343641,0.0003656985,0.0002390876,0.0002680441,0.000178118,0.0001146447],"category_scores_gemma":[0.000303185,0.0004475566,0.0003028023,0.0008682173,0.0002134199,0.0004811751,0.0001248229,0.0006749435,0.0005457971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005095578,"about_ca_system_score_gemma":0.0004340404,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02033013,"about_ca_topic_score_gemma":0.004597378,"domain_scores_codex":[0.996249,0.0003714209,0.0008902238,0.0009361354,0.0007393389,0.0008138836],"domain_scores_gemma":[0.9971546,0.0007322547,0.0004470898,0.001058217,0.0002477624,0.0003600952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.537554,0.002640698,0.4548552,0.00003697441,0.0006221171,0.0001016184,0.001583901,0.0000394688,0.00001545363,0.00000715132,0.001143532,0.001399897],"study_design_scores_gemma":[0.6238386,0.003375047,0.3700543,0.0002903759,0.0008147429,0.000005809115,0.0005060954,0.0001067835,0.00005810457,0.00004628395,0.0004905346,0.0004133289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856567,0.0001526952,0.00003143793,0.0009324825,0.0007174282,0.008971809,0.0001468656,0.0004639697,0.002926548],"genre_scores_gemma":[0.9947482,0.0002867967,0.00007860176,0.0001517081,0.001376443,0.002155621,0.0003952209,0.00007575227,0.0007316498],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08628462,"threshold_uncertainty_score":0.9997976,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2164903312","doi":"10.1128/aac.45.10.2733-2739.2001","title":"Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults","year":2001,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Gilead Sciences (Canada)","funders":"National Institutes of Health; National Center for Research Resources; National Institute of Mental Health; Johns Hopkins University; University of Washington; Gilead Sciences","keywords":"Pharmacokinetics; Medicine; Placebo; Adverse effect; Dosing; Reverse-transcriptase inhibitor; Pharmacology; Discontinuation; Internal medicine; Virus; Gastroenterology; Sida; Virology; Viral disease; Pathology","authors":[{"name":"Patricia Barditch‐Crovo","is_ca":false},{"name":"Steven G. Deeks","is_ca":false},{"name":"Ann Collier","is_ca":false},{"name":"Sharon Safrin","is_ca":false},{"name":"Dion F. Coakley","is_ca":true},{"name":"Michael D. Miller","is_ca":true},{"name":"Brian P. Kearney","is_ca":true},{"name":"Rebecca Coleman","is_ca":true},{"name":"Patrick D. Lamy","is_ca":true},{"name":"James O. Kahn","is_ca":false},{"name":"Ian McGowan","is_ca":true},{"name":"Paul S. Lietman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01141155838644725,"gpt":0.2844821790997805,"spread":0.2730706207133333,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001302167,0.0002050429,0.0004374889,0.00009878861,0.0001332752,0.000009893709,0.00008447617,0.00007371046,0.00008045945],"category_scores_gemma":[0.000007099103,0.0001395777,0.00009250896,0.0002532369,0.0002053172,0.00006910742,0.00006760947,0.0001202462,5.777375e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002752459,"about_ca_system_score_gemma":0.00004329559,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002307332,"about_ca_topic_score_gemma":0.00002502543,"domain_scores_codex":[0.9989389,0.00004613148,0.0003847798,0.0002552338,0.0001548343,0.0002201189],"domain_scores_gemma":[0.9995164,0.00001414682,0.0001947407,0.0001859267,0.00004390901,0.00004490634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.04741923,0.01105432,0.09042352,0.0001414181,0.0002440841,0.00001983368,0.002302361,7.821333e-7,0.7698993,0.00001834695,0.0005971612,0.07787965],"study_design_scores_gemma":[0.335844,0.004305596,0.1901,0.0004626561,0.0001881133,0.00003014985,0.00005762045,0.0002292372,0.463224,0.00001873542,0.005163785,0.0003760552],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997593,0.00004772349,0.000007988462,0.00107957,0.00008414844,0.0008046601,0.00003235987,0.00001238928,0.0003381274],"genre_scores_gemma":[0.9956183,0.003005803,0.00003508329,0.0002347795,0.00003339167,0.000004099933,0.00002098153,0.00001877785,0.001028712],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3066753,"threshold_uncertainty_score":0.5691815,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2106720283","doi":"10.1097/qad.0b013e328011e691","title":"HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance","year":2006,"lang":"en","type":"review","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":331,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Reverse transcriptase; Drug resistance; HIV drug resistance; Virology; Nucleoside Reverse Transcriptase Inhibitor; Resistance mutation; Reverse-transcriptase inhibitor; Mutation; Protease inhibitor (pharmacology); Protease; Biology; Human immunodeficiency virus (HIV); Medicine; Genetics; Viral load; Polymerase chain reaction; Antiretroviral therapy; Gene; Enzyme","authors":[{"name":"Robert W. Shafer","is_ca":false},{"name":"Soo‐Yon Rhee","is_ca":false},{"name":"Deenan Pillay","is_ca":false},{"name":"Veronica Miller","is_ca":false},{"name":"Paul Sandstrom","is_ca":true},{"name":"Jonathan Schapiro","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Diane Bennett","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02809935969644671,"gpt":0.3117433572995661,"spread":0.2836439976031194,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002517593,0.0003743711,0.001199373,0.0001668427,0.0001231628,0.00002355967,0.00007011028,0.0001273929,0.00003321162],"category_scores_gemma":[0.00007822355,0.0002910855,0.0003230436,0.0002579271,0.00007427228,0.00004994667,0.00001152903,0.000159088,0.00005253369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001262443,"about_ca_system_score_gemma":0.0003533438,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009468168,"about_ca_topic_score_gemma":0.00001127777,"domain_scores_codex":[0.9985224,0.00008034849,0.00048906,0.0004603592,0.0001790509,0.0002687692],"domain_scores_gemma":[0.9991394,0.0001648443,0.0001547006,0.0003163487,0.00007959484,0.000145171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001273329,0.0004476944,0.001430919,0.06484824,0.0008750217,0.0003277811,0.000356557,9.687753e-8,0.00000126626,0.0008319628,0.4151891,0.515564],"study_design_scores_gemma":[0.001239253,0.00002617604,0.00002638796,0.005029594,0.001186054,0.00002475428,0.00001504636,8.657046e-7,0.000002617337,0.00006774004,0.9921105,0.0002709946],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001799333,0.9932454,0.0002298746,0.0007865232,0.00009390477,0.003512063,0.0007303435,0.0000701961,0.001313696],"genre_scores_gemma":[0.00001569425,0.7719994,0.01035904,0.00004370587,0.0001061455,0.001245641,0.002774207,0.00005717366,0.213399],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5769214,"threshold_uncertainty_score":0.9999541,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W15969640","doi":"10.1177/135965350000500112","title":"The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan","year":2000,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Regimen; Internal medicine; Medicine; Drug resistance; Genotyping; Confounding; Viral load; HIV drug resistance; Observational study; Odds ratio; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genotype; Biology","authors":[{"name":"Victor DeGruttola","is_ca":false},{"name":"Lynn P. Dix","is_ca":false},{"name":"Richard T. D’Aquila","is_ca":false},{"name":"Dan Holder","is_ca":false},{"name":"Andrew Phillips","is_ca":false},{"name":"Mounir Ait‐Khaled","is_ca":false},{"name":"John D. Baxter","is_ca":false},{"name":"Philippe Clevenbergh","is_ca":false},{"name":"Scott Hammer","is_ca":false},{"name":"Richard Harrigan","is_ca":true},{"name":"David Katzenstein","is_ca":false},{"name":"Randall Lanier","is_ca":false},{"name":"Michael D. Miller","is_ca":false},{"name":"Michael F. Para","is_ca":false},{"name":"Sabine Yerly","is_ca":false},{"name":"Andrew Zolopa","is_ca":false},{"name":"Jeffrey S. Murray","is_ca":false},{"name":"Amy K. Patick","is_ca":false},{"name":"Veronica Miller","is_ca":false},{"name":"Steven Castillo","is_ca":false},{"name":"Louise Pedneault","is_ca":false},{"name":"John W. Mellors","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05242918270470057,"gpt":0.345406405668464,"spread":0.2929772229637635,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002209614,0.0002805286,0.001086568,0.0004905828,0.0003993859,0.00005497195,0.0001418174,0.00005905097,0.00002733526],"category_scores_gemma":[0.0001733083,0.0001781927,0.0001601068,0.002367121,0.000257197,0.000208222,0.00006167585,0.0001430003,0.000001487489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001548453,"about_ca_system_score_gemma":0.00008467973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004502323,"about_ca_topic_score_gemma":0.0002659473,"domain_scores_codex":[0.9975802,0.0004901853,0.0005061654,0.0006744497,0.0004845674,0.000264376],"domain_scores_gemma":[0.9981589,0.0006300635,0.0002018753,0.0007334727,0.0002008926,0.0000747454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01546041,0.00008058695,0.9444903,0.000006173731,0.02331007,0.0000164539,0.007753913,0.000005835244,0.001278422,0.00002853711,0.0004057873,0.007163484],"study_design_scores_gemma":[0.00384717,0.0003151297,0.9838695,0.00007246486,0.005251337,7.273121e-7,0.001235322,0.0007506815,0.002108373,0.0001492493,0.0021383,0.0002617413],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908755,0.005173685,0.0002626834,0.002412884,0.00001321562,0.000749699,0.0003625176,0.00003535549,0.0001144475],"genre_scores_gemma":[0.9846761,0.007385265,0.002319124,0.00005573115,0.00004276688,0.00001438865,0.000162161,0.00002231491,0.005322108],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03937918,"threshold_uncertainty_score":0.7266489,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133117185","doi":"10.1093/infdis/jiu051","title":"Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study","year":2014,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; Gilead Sciences; ViiV Healthcare; GlaxoSmithKline; National Institute of Allergy and Infectious Diseases; Pfizer; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Medicine; Discontinuation; Regimen; Tolerability; Integrase inhibitor; Adverse effect; Viral load; Internal medicine; Population; Phases of clinical research; Pharmacology; Clinical trial; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"Antonella Castagna","is_ca":false},{"name":"Franco Maggiolo","is_ca":false},{"name":"Giovanni Penco","is_ca":false},{"name":"David P. Wright","is_ca":false},{"name":"Anthony Mills","is_ca":false},{"name":"Robert Grossberg","is_ca":false},{"name":"Jean‐Michel Molina","is_ca":false},{"name":"Julie Chas","is_ca":false},{"name":"J. Durant","is_ca":false},{"name":"Santiago Moreno","is_ca":false},{"name":"Manuela Doroana","is_ca":false},{"name":"Mounir Ait‐Khaled","is_ca":false},{"name":"J. Huang","is_ca":true},{"name":"Sherene Min","is_ca":false},{"name":"Ivy Song","is_ca":false},{"name":"Cindy Vavro","is_ca":false},{"name":"Garrett Nichols","is_ca":false},{"name":"Jane Yeo","is_ca":false},{"name":"Judith A. Aberg","is_ca":false},{"name":"Bisher Akil","is_ca":false},{"name":"José Ramón Arribas","is_ca":false},{"name":"J.G. Baril","is_ca":false},{"name":"F. Blanco Quintana","is_ca":false},{"name":"Gary Blick","is_ca":false},{"name":"Vicente Boix Martínez","is_ca":false},{"name":"Olivier Bouchaud","is_ca":false},{"name":"Teresa Branco","is_ca":false},{"name":"U. Fritz Bredeek","is_ca":false},{"name":"MANUEL C. IGLESIAS","is_ca":false},{"name":"Nathan Clumeck","is_ca":false},{"name":"Brian Conway","is_ca":false},{"name":"E DeJesus","is_ca":false},{"name":"Jean L. Delassus","is_ca":false},{"name":"P. de Truchis","is_ca":false},{"name":"Giovanni Di Perri","is_ca":false},{"name":"Massimo Di Pietro","is_ca":false},{"name":"Joan Duggan","is_ca":false},{"name":"Claudine Duvivier","is_ca":false},{"name":"Richard Elion","is_ca":false},{"name":"Joseph Eron","is_ca":false},{"name":"Douglas N. Fish","is_ca":false},{"name":"Joseph Gathe","is_ca":false},{"name":"Richard Haubrich","is_ca":false},{"name":"Heather Henderson","is_ca":false},{"name":"Charles B. Hicks","is_ca":false},{"name":"Laurent Hocqueloux","is_ca":false},{"name":"Sally Hodder","is_ca":false},{"name":"CB Hsiao","is_ca":false},{"name":"Christine Katlama","is_ca":false},{"name":"Michael J. Kozal","is_ca":false},{"name":"Princy Kumar","is_ca":false},{"name":"Sujata N. Lalla-Reddy","is_ca":false},{"name":"Adriano Lazzarin","is_ca":false},{"name":"F Leoncini","is_ca":false},{"name":"Josep M. Llibre","is_ca":false},{"name":"Kamal Mansinho","is_ca":false},{"name":"Philippe Morlat","is_ca":false},{"name":"Karam Mounzer","is_ca":false},{"name":"M. Murphy","is_ca":false},{"name":"C. Newman","is_ca":false},{"name":"Thuy Nguyen","is_ca":false},{"name":"Bacel Nseir","is_ca":false},{"name":"Patrick Philibert","is_ca":false},{"name":"Gilles Pialoux","is_ca":false},{"name":"Isabelle Poizot‐Martin","is_ca":false},{"name":"Moti Ramgopal","is_ca":false},{"name":"Gary Richmond","is_ca":false},{"name":"Dominique Salmon Ceron","is_ca":false},{"name":"Paul E. Sax","is_ca":false},{"name":"A. Scarsella","is_ca":false},{"name":"Michael Sension","is_ca":false},{"name":"Peter Shalit","is_ca":false},{"name":"L Sighinolfi","is_ca":false},{"name":"Louis Sloan","is_ca":false},{"name":"Catherine B. Small","is_ca":false},{"name":"David Stein","is_ca":false},{"name":"K. Tashima","is_ca":false},{"name":"Pablo Tebas","is_ca":false},{"name":"Carlo Torti","is_ca":false},{"name":"Marc Tribble","is_ca":false},{"name":"Didier Troisvallets","is_ca":false},{"name":"Christos Tsoukas","is_ca":false},{"name":"Pompeyo Viciana Fernandez","is_ca":false},{"name":"Derek Ward","is_ca":false},{"name":"Darrell P. Wheeler","is_ca":false},{"name":"Timothy Wilkin","is_ca":false},{"name":"Guy-Patrick Yeni","is_ca":false},{"name":"J. Louise Martin-Carpenter","is_ca":false},{"name":"G. Uhlenbrauck","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008909296242199214,"gpt":0.2590626394812267,"spread":0.2501533432390275,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004928862,0.0002595513,0.0005807072,0.0002234497,0.0001867646,0.00002794956,0.000195796,0.00003840797,0.00001353719],"category_scores_gemma":[0.000358997,0.0001058152,0.000119176,0.0005005312,0.0001948243,0.0001402376,0.00005940153,0.0002530203,0.000001636002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001173474,"about_ca_system_score_gemma":0.0002094224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001078072,"about_ca_topic_score_gemma":0.0001461595,"domain_scores_codex":[0.9978314,0.0003473342,0.0007510048,0.0001774292,0.0006435242,0.0002493206],"domain_scores_gemma":[0.9982811,0.0002882453,0.000669868,0.0003644714,0.0002315587,0.0001648133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02621467,0.008799764,0.9538406,0.00004006295,0.0003249153,0.00005697914,0.005644571,0.00002315366,0.0004867227,0.00001681549,0.0004457198,0.004106083],"study_design_scores_gemma":[0.06212386,0.01097605,0.9211605,0.000596695,0.00100355,0.00005527506,0.002704159,0.00004043368,0.0006260991,0.00008691,0.0004122486,0.0002142582],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984007,0.0001569112,0.00002748257,0.0002674839,0.0001259365,0.0007829117,0.00002968988,0.00001500155,0.0001939157],"genre_scores_gemma":[0.9992589,0.0000584591,0.00003596192,0.0000830374,0.00005648756,0.00001266619,0.000007773615,0.00002161076,0.0004651266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03590919,"threshold_uncertainty_score":0.431502,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2318022415","doi":"10.1056/nejm200103293441307","title":"Interactions among Drugs for HIV and Opportunistic Infections","year":2001,"lang":"en","type":"review","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":325,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Drug; Human immunodeficiency virus (HIV); Intensive care medicine; Opportunistic infection; Antiretroviral therapy; Antiretroviral drug; Immunology; Viral disease; Pharmacology; Viral load","authors":[{"name":"Stephen C. Piscitelli","is_ca":false},{"name":"Keith Gallicano","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05834285616609883,"gpt":0.3637505953102433,"spread":0.3054077391441445,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005666979,0.0003454433,0.001941644,0.0006778351,0.0001002277,0.00001505108,0.00007523666,0.0001234725,0.0003650564],"category_scores_gemma":[0.0004754828,0.0002021421,0.000294907,0.0002617937,0.0001122456,0.00008501568,0.00002028766,0.0005564839,0.000008360322],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001672216,"about_ca_system_score_gemma":0.0006855703,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001337283,"about_ca_topic_score_gemma":0.00002067538,"domain_scores_codex":[0.9982003,0.00007056841,0.001034796,0.0001877057,0.0002934453,0.0002132148],"domain_scores_gemma":[0.9975234,0.0007835051,0.0007439312,0.0001621018,0.0002112899,0.0005757411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005933908,0.0001077625,0.0002844344,0.001899553,0.0008560532,0.0002645419,0.0003937553,1.554559e-7,1.781826e-7,0.00007137679,0.05742826,0.9386346],"study_design_scores_gemma":[0.01625136,0.0005427193,0.00002793958,0.02281105,0.006984677,0.007219239,0.0001056068,0.000007458538,1.264916e-7,0.00008452308,0.9458236,0.0001416772],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005280197,0.9871712,0.001914132,0.005892526,0.0009977493,0.0007480355,0.00001615335,0.00002004082,0.003187357],"genre_scores_gemma":[0.00008493885,0.9574903,0.0006375901,0.00006691,0.004546343,0.00002175131,0.0001627683,0.00004226119,0.03694715],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9384929,"threshold_uncertainty_score":0.8243113,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2144984387","doi":"10.1016/s0140-6736(06)69154-x","title":"Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials","year":2006,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"International AIDS Society","keywords":"Ritonavir; Regimen; Medicine; Protease inhibitor (pharmacology); Internal medicine; Viral load; Randomized controlled trial; Pharmacology; Gastroenterology; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"Charles B. Hicks","is_ca":false},{"name":"Pedro Cahn","is_ca":false},{"name":"David A. Cooper","is_ca":false},{"name":"Sharon Walmsley","is_ca":true},{"name":"Christine Katlama","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"Adriano Lazzarin","is_ca":false},{"name":"Margaret Johnson","is_ca":false},{"name":"Dietmar Neubacher","is_ca":false},{"name":"Douglas L. Mayers","is_ca":false},{"name":"Hernan Valdez","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1782479061759761,"gpt":0.4109949463905229,"spread":0.2327470402145468,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006325213,0.0003106139,0.00303394,0.0004153364,0.00006450728,0.00002306954,0.0005096174,0.00006045313,0.00001906178],"category_scores_gemma":[0.0003733578,0.0001637639,0.0001358538,0.001048925,0.0002464808,0.0003580815,0.00006427295,0.00007503577,2.52859e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003562107,"about_ca_system_score_gemma":0.00015147,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005617565,"about_ca_topic_score_gemma":0.01004989,"domain_scores_codex":[0.9938919,0.002800686,0.001807047,0.0004792112,0.00077978,0.0002413651],"domain_scores_gemma":[0.9949906,0.00176338,0.001688255,0.0009935914,0.0005304697,0.00003367896],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7293165,0.01569096,0.2419517,0.0001024441,0.002545236,0.000002021052,0.00811934,0.0009178708,0.0008190846,0.00005941177,0.00002347646,0.0004519682],"study_design_scores_gemma":[0.7363588,0.001784939,0.2253653,0.0004696604,0.003910892,4.824608e-8,0.003054058,0.02801574,0.000827099,0.00007762309,5.503039e-7,0.0001352778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897441,0.0001728982,0.00003303496,0.0001005601,0.00002243709,0.009340111,0.0005331952,0.000008136482,0.00004548027],"genre_scores_gemma":[0.9861572,0.00004295679,0.001444456,0.000005820301,0.000009216236,0.0005256859,0.01172375,0.0000210281,0.00006986273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02709787,"threshold_uncertainty_score":0.8492115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2330399120","doi":"10.1097/00002030-200301030-00001","title":"A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","year":2003,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Biology; Virology; Efavirenz; Reverse transcriptase; Nevirapine; Genotype; Mutation; Genetics; Gene; Virus; Polymerase chain reaction; Viral load","authors":[{"name":"Bluma Brenner","is_ca":true},{"name":"Dan Turner","is_ca":false},{"name":"Maureen Oliveira","is_ca":false},{"name":"Daniela Moïsi","is_ca":false},{"name":"Mervi Detorio","is_ca":false},{"name":"Mauricio Carobene","is_ca":false},{"name":"Richard Marlink","is_ca":false},{"name":"Jonathan Schapiro","is_ca":false},{"name":"Michel Roger","is_ca":false},{"name":"Mark A. Wainberg","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0200485203743622,"gpt":0.2915979826713447,"spread":0.2715494622969825,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002094106,0.0002662694,0.0003782418,0.0003547763,0.00009551882,0.00004346927,0.00007972454,0.0001014515,0.0001869206],"category_scores_gemma":[0.0001964444,0.0002523466,0.0001008089,0.0006586675,0.00004795385,0.0001598619,0.00001261661,0.0001414739,0.0006214547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002876837,"about_ca_system_score_gemma":0.0001870311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000566976,"about_ca_topic_score_gemma":0.0001822652,"domain_scores_codex":[0.9982814,0.00006362648,0.0004672132,0.0004502657,0.0003284735,0.0004090784],"domain_scores_gemma":[0.9991727,0.00005472583,0.00005076387,0.0002930905,0.00007921547,0.0003495315],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003310144,0.001755889,0.5322053,0.0003441168,0.0004004436,0.002914945,0.03818966,0.0002022575,0.3140272,0.00214028,0.09845345,0.006056221],"study_design_scores_gemma":[0.01358432,0.0007157596,0.08903131,0.0009419409,0.000216823,0.00002875855,0.002735019,0.00001447592,0.6183511,0.0001464978,0.273354,0.0008799422],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917997,0.0000820428,0.0004891169,0.001799641,0.0002268253,0.001013729,0.00003119377,0.00006877422,0.004489042],"genre_scores_gemma":[0.9725967,0.00000855714,0.01143111,0.00269234,0.00004256937,0.0001631585,0.00004165744,0.00004077705,0.0129831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4431741,"threshold_uncertainty_score":0.9999928,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2097847166","doi":"10.1371/journal.pmed.0020112","title":"Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration","year":2005,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; Doris Duke Charitable Foundation","keywords":"Reverse transcriptase; Virology; Drug resistance; Genotype; Biology; Lentivirus; Protease; Human immunodeficiency virus (HIV); Medicine; Genetics; Polymerase chain reaction; Viral disease; Gene; Enzyme","authors":[{"name":"Rami Kantor","is_ca":false},{"name":"David Katzenstein","is_ca":false},{"name":"Brad Efron","is_ca":false},{"name":"A.P. Carvalho","is_ca":false},{"name":"Brian Wynhoven","is_ca":true},{"name":"Patricia Cane","is_ca":false},{"name":"John Clarke","is_ca":false},{"name":"Sunee Sirivichayakul","is_ca":false},{"name":"Marcelo A. Soares","is_ca":false},{"name":"Joke Snoeck","is_ca":false},{"name":"Candice Pillay","is_ca":false},{"name":"H Rudich","is_ca":false},{"name":"Rosângela Rodrigues","is_ca":false},{"name":"África Holguín","is_ca":false},{"name":"Koya Ariyoshi","is_ca":false},{"name":"María Belén Bouzas","is_ca":false},{"name":"Pedro Cahn","is_ca":false},{"name":"Wataru Sugiura","is_ca":false},{"name":"Vincent Soriano","is_ca":false},{"name":"Luís Fernando de Macedo Brígido","is_ca":false},{"name":"Zehava Grossman","is_ca":false},{"name":"Lynn Morris","is_ca":false},{"name":"Anne‐Mieke Vandamme","is_ca":false},{"name":"Amílcar Tanuri","is_ca":false},{"name":"Praphan Phanuphak","is_ca":false},{"name":"Jonathan Weber","is_ca":false},{"name":"Deenan Pillay","is_ca":false},{"name":"P. Richard Harrigan","is_ca":true},{"name":"Ricardo Camacho","is_ca":false},{"name":"Jonathan Schapiro","is_ca":false},{"name":"Robert W. Shafer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01993683919710418,"gpt":0.294829505157253,"spread":0.2748926659601488,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001635892,0.0001602609,0.0004041645,0.00008100883,0.00002696564,0.000002601286,0.00002800645,0.00006001115,0.00004787375],"category_scores_gemma":[0.0001625429,0.0001013198,0.00003410433,0.0002718105,0.0001521905,0.00006158327,0.00000581426,0.00006669318,0.000003945974],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009343565,"about_ca_system_score_gemma":0.0001722145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008221478,"about_ca_topic_score_gemma":0.00001176666,"domain_scores_codex":[0.9989811,0.00004031965,0.0003456197,0.0002045183,0.000293082,0.0001354177],"domain_scores_gemma":[0.9993719,0.00003285549,0.0001392459,0.0001720441,0.0001367516,0.0001471948],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02858736,0.002490645,0.7696109,0.0003845137,0.001088077,0.0001246029,0.008315666,0.000003492481,0.1345331,0.0003505619,0.02171963,0.03279148],"study_design_scores_gemma":[0.07601239,0.02172299,0.8521276,0.00184015,0.0009606814,0.0000789242,0.0006317188,0.0006600948,0.03998375,0.00008066685,0.005479816,0.0004211928],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989661,0.001249127,0.000004876073,0.007473835,0.00002162794,0.0007713933,0.000152414,0.00001764893,0.0006480346],"genre_scores_gemma":[0.9978467,0.0006271218,0.00057796,0.0001136989,0.00009256612,0.000009842853,0.000105569,0.000009857639,0.0006166732],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09454935,"threshold_uncertainty_score":0.4131702,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2040027667","doi":"10.1097/qai.0b013e31819675e9","title":"The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time","year":2009,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":317,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Simon Fraser University; University of British Columbia; St. Paul's Hospital","funders":"National Institute of Mental Health; University of British Columbia","keywords":"Efavirenz; Lopinavir; Atazanavir; Hazard ratio; Medicine; Internal medicine; Nevirapine; Ritonavir; Reverse-transcriptase inhibitor; Confidence interval; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology","authors":[{"name":"Viviane D. Lima","is_ca":true},{"name":"Richard Harrigan","is_ca":true},{"name":"David R. Bangsberg","is_ca":false},{"name":"Robert S. Hogg","is_ca":true},{"name":"Robert Gross","is_ca":false},{"name":"Benita Yip","is_ca":true},{"name":"Julio Montaner","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01268521441145212,"gpt":0.2776353931414786,"spread":0.2649501787300265,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009618501,0.0002937147,0.000839923,0.0002399577,0.0001927242,0.00003745815,0.0002273644,0.00009156599,0.00002039085],"category_scores_gemma":[0.0001818673,0.0001603297,0.0002772234,0.000387119,0.0002317338,0.0002054369,0.00002967731,0.0001470525,0.00001480558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000927205,"about_ca_system_score_gemma":0.0001236375,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007265715,"about_ca_topic_score_gemma":1.643077e-7,"domain_scores_codex":[0.9978298,0.000194669,0.0007226147,0.0002178104,0.0006977883,0.0003373372],"domain_scores_gemma":[0.9982907,0.0004669549,0.000609674,0.0003724056,0.0001589803,0.0001012689],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.02602888,0.00396397,0.188353,0.0002155637,0.004037072,0.001317648,0.006394386,0.00003968827,0.3358754,0.001023241,0.002873122,0.4298781],"study_design_scores_gemma":[0.01065894,0.03300455,0.8626512,0.0005775692,0.0004003854,0.0004222624,0.0001008798,0.0003123256,0.09055938,0.0009283412,0.00008747213,0.0002967486],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943542,0.003752499,0.000008793986,0.0006780353,0.0001663268,0.0004117569,0.00000554072,0.00002635699,0.0005965019],"genre_scores_gemma":[0.9968171,0.00107374,0.00008020331,0.00003648455,0.00002013969,0.000004207408,0.000005063663,0.00001940256,0.00194372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6742982,"threshold_uncertainty_score":0.6538057,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2014005798","doi":"10.1097/01.aids.0000199825.34241.49","title":"Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":316,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; U.S. Public Health Service","keywords":"Drug resistance; Nelfinavir; HIV drug resistance; Reverse-transcriptase inhibitor; Reverse transcriptase; Virology; Drug; Biology; Protease inhibitor (pharmacology); Population; Nevirapine; Medicine; Internal medicine; Virus; Viral disease; Pharmacology; Sida; Viral load; Polymerase chain reaction; Antiretroviral therapy; Genetics","authors":[{"name":"David R. Bangsberg","is_ca":false},{"name":"Edward P. Acosta","is_ca":false},{"name":"Reena Gupta","is_ca":false},{"name":"David Guzman","is_ca":false},{"name":"Elise D. Riley","is_ca":false},{"name":"P. Richard Harrigan","is_ca":true},{"name":"Neil Parkin","is_ca":false},{"name":"Steven G. Deeks","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01743706402851803,"gpt":0.2396594699764665,"spread":0.2222224059479485,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002114261,0.0001770881,0.00025069,0.00006293058,0.000194334,0.00001801118,0.00004056441,0.0001148646,0.00005659809],"category_scores_gemma":[0.00008877033,0.0001405207,0.00007513715,0.0001275239,0.00008777152,0.0001033349,0.000009933588,0.0001313815,0.0000199784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004961599,"about_ca_system_score_gemma":0.00004850213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002557521,"about_ca_topic_score_gemma":0.00001755222,"domain_scores_codex":[0.9989796,0.00004148946,0.0002786707,0.0003079725,0.0001586058,0.0002336838],"domain_scores_gemma":[0.9995099,0.0001026897,0.00005550178,0.000153278,0.00004714253,0.0001315041],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002371029,0.001418429,0.4883578,0.000428483,0.0001921986,0.0002456667,0.001171101,0.000002986194,0.03974527,0.00279132,0.4605103,0.002765467],"study_design_scores_gemma":[0.05477758,0.003559006,0.2788915,0.001398772,0.001863963,0.00009111289,0.002107352,0.0005414716,0.1290217,0.01292177,0.5124478,0.002377926],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926611,0.0004203373,0.0011928,0.002953311,0.00007009794,0.001424944,0.00007439128,0.00007300334,0.001130022],"genre_scores_gemma":[0.9632173,0.0000149755,0.01022537,0.0001459307,0.00007658548,0.000468684,0.0002494775,0.00001861668,0.0255831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2094662,"threshold_uncertainty_score":0.5730266,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2172274075","doi":"10.1086/431199","title":"Efficacy of Antiretroviral Therapy Programs in Resource‐Poor Settings: A Meta‐analysis of the Published Literature","year":2005,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Viral load; Observational study; Meta-analysis; MEDLINE; Antiretroviral therapy; Internal medicine; Human immunodeficiency virus (HIV); Intensive care medicine; Family medicine","authors":[{"name":"Louise C. Ivers","is_ca":false},{"name":"David C. Kendrick","is_ca":false},{"name":"Karen Doucette","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1037390807758232,"gpt":0.4067970990395495,"spread":0.3030580182637263,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007711083,0.0005882244,0.006377327,0.0007674768,0.000054476,0.00006989555,0.0003550923,0.0005045255,0.0001562371],"category_scores_gemma":[0.001302793,0.0002988127,0.009045525,0.004136373,0.0003534856,0.00008635136,0.0001377954,0.0007357887,0.000006570717],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009647571,"about_ca_system_score_gemma":0.0005947168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007454922,"about_ca_topic_score_gemma":0.00001867844,"domain_scores_codex":[0.9951222,0.0009371748,0.002338033,0.0007394374,0.0005151384,0.0003480352],"domain_scores_gemma":[0.9960104,0.00121215,0.001339722,0.001009903,0.0001952144,0.000232629],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009775179,0.006621567,0.0702929,0.003629293,0.1683347,0.00003297359,0.0001044697,0.000001683885,2.056791e-8,0.0000198275,0.001644786,0.74922],"study_design_scores_gemma":[0.002120939,0.0003718267,0.01054782,0.004407488,0.3290757,0.000004093178,0.000009957114,0.000005210435,2.611531e-7,0.000008896784,0.6531942,0.0002536872],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002703824,0.9938731,5.264966e-7,0.0004718918,0.0001000423,0.002328384,0.0001464699,0.00007474806,0.0003009732],"genre_scores_gemma":[0.007569273,0.9894245,0.00002890491,0.0003544948,0.0002171326,0.0002971117,0.0009215496,0.00005962779,0.001127433],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7489663,"threshold_uncertainty_score":0.9999464,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120293408","doi":"10.1016/s1473-3099(09)70328-7","title":"Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review","year":2010,"lang":"en","type":"review","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Resistance mutation; Lamivudine; Drug resistance; Regimen; Medicine; Reverse-transcriptase inhibitor; Reverse transcriptase; Virology; Genotyping; Internal medicine; Antiretroviral therapy; Etravirine; Protease inhibitor (pharmacology); Viral load; Human immunodeficiency virus (HIV); Biology; Genotype; Virus; Polymerase chain reaction; Genetics","authors":[{"name":"Roos E. Barth","is_ca":false},{"name":"Maarten F. Schim van der Loeff","is_ca":true},{"name":"Rob Schuurman","is_ca":false},{"name":"Andy I. M. Hoepelman","is_ca":false},{"name":"Annemarie M. J. Wensing","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0288175057813383,"gpt":0.3038787431304422,"spread":0.2750612373491039,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000249462,0.0006339527,0.005423617,0.0002747725,0.00004984606,0.00002164479,0.0002320189,0.0002258345,0.00001973107],"category_scores_gemma":[0.0006776295,0.0003097154,0.0008064009,0.0005950704,0.0001155181,0.00004804041,0.00006517593,0.0003754083,0.00008037333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004033025,"about_ca_system_score_gemma":0.0002799658,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005518407,"about_ca_topic_score_gemma":0.0002620604,"domain_scores_codex":[0.9968529,0.0005463966,0.001255462,0.0004506548,0.0003793202,0.0005152125],"domain_scores_gemma":[0.9980912,0.0003366334,0.0006150018,0.0007295568,0.00009470434,0.0001329565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001333349,0.003840816,0.07225567,0.7500637,0.0007767695,0.0001746769,0.0001262806,5.407979e-8,1.017628e-7,0.00001785931,0.0006260747,0.1719847],"study_design_scores_gemma":[0.009577946,0.001550982,0.005160052,0.8667639,0.01690016,0.00005515042,0.00001120847,0.000002723716,0.000001540724,0.00005633714,0.09920962,0.0007104101],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009684603,0.9806441,2.035101e-7,0.00008016542,0.0001455858,0.008901684,0.0001607939,0.00009713606,0.000285697],"genre_scores_gemma":[0.005836307,0.9892776,0.00000837508,0.00007994232,0.00008236204,0.003889007,0.000516411,0.00004516239,0.0002648143],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1712743,"threshold_uncertainty_score":0.9999355,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2122026430","doi":"10.1093/infdis/jis750","title":"Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study","year":2012,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Dolutegravir; Raltegravir; Regimen; Cohort; Medicine; Viral load; Integrase inhibitor; Elvitegravir; Dosing; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"Joseph J. Eron","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"J. Durant","is_ca":false},{"name":"Christine Katlama","is_ca":false},{"name":"Princy Kumar","is_ca":false},{"name":"Adriano Lazzarin","is_ca":false},{"name":"Isabelle Poizot‐Martin","is_ca":false},{"name":"Gary Richmond","is_ca":false},{"name":"Vincent Soriano","is_ca":false},{"name":"Mounir Ait‐Khaled","is_ca":false},{"name":"Tamio Fujiwara","is_ca":false},{"name":"Jenny Huang","is_ca":true},{"name":"Sherene Min","is_ca":false},{"name":"Cindy Vavro","is_ca":false},{"name":"Jane Yeo","is_ca":false},{"name":"Sharon Walmsley","is_ca":false},{"name":"Joseph Cox","is_ca":false},{"name":"Jacques Reynes","is_ca":false},{"name":"Philippe Morlat","is_ca":false},{"name":"Daniel Vittecoq","is_ca":false},{"name":"Jean‐Michel Livrozet","is_ca":false},{"name":"Pompeyo Viciana Fernández","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Edwin DeJesus","is_ca":false},{"name":"Jerome DeVente","is_ca":false},{"name":"Jacob Lalezari","is_ca":false},{"name":"Lewis McCurdy","is_ca":false},{"name":"Louis A. Sloan","is_ca":false},{"name":"Benjamin Young","is_ca":false},{"name":"Anthony LaMarca","is_ca":false},{"name":"Trevor Hawkins","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01656090380541293,"gpt":0.27322790795775,"spread":0.2566670041523371,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003685675,0.000183063,0.000447441,0.0001635039,0.0001215068,0.000008659238,0.00007043425,0.00003023449,0.00001230123],"category_scores_gemma":[0.0002014902,0.00007988141,0.0000978079,0.000502673,0.0001311719,0.0001188373,0.00003043026,0.0001278351,0.000001049317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001861304,"about_ca_system_score_gemma":0.0002488032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002540904,"about_ca_topic_score_gemma":0.0002686665,"domain_scores_codex":[0.998581,0.0002551683,0.0005458521,0.00009476567,0.0003312851,0.0001919283],"domain_scores_gemma":[0.9986477,0.0003311473,0.0005011992,0.0002403621,0.0001573617,0.0001221536],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01060298,0.004349699,0.9724762,0.00002683454,0.0004579825,0.00001867083,0.01019668,0.00006053783,0.0006181862,0.00001615312,0.00004247184,0.001133601],"study_design_scores_gemma":[0.01306034,0.003165537,0.9779921,0.000310328,0.000922617,0.0001371213,0.002121887,0.000003247846,0.001941012,0.0000119547,0.0002472982,0.00008652069],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978058,0.0009133892,0.000006181,0.0001794711,0.0001364493,0.0005713886,0.000008806245,0.000009546426,0.0003689176],"genre_scores_gemma":[0.9992251,0.00038781,0.00002149092,0.00001307799,0.00007515361,0.000005289412,0.000002400392,0.00001360261,0.0002560411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008074795,"threshold_uncertainty_score":0.325747,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2112519486","doi":"10.1182/blood-2009-02-205153","title":"Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University; Hamilton Health Sciences; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"EIF4E; Ribavirin; Myeloid leukemia; Cancer research; Leukemia; Medicine; Myeloid; Clinical trial; Acute leukemia; Initiation factor; Translation (biology); Biology; Oncology; Immunology; Internal medicine; Messenger RNA; Gene; Genetics; Virus","authors":[{"name":"Sarit Assouline","is_ca":true},{"name":"Biljana Čuljković","is_ca":true},{"name":"Eftihia Cocolakis","is_ca":true},{"name":"Caroline Rousseau","is_ca":true},{"name":"Nathalie Beslu","is_ca":true},{"name":"Abdellatif Amri","is_ca":true},{"name":"Stephen Caplan","is_ca":true},{"name":"Brian Leber","is_ca":true},{"name":"Denis‐Claude Roy","is_ca":true},{"name":"Wilson H. Miller","is_ca":true},{"name":"Katherine L. B. Borden","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01867370532849957,"gpt":0.3086300032636587,"spread":0.2899562979351591,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004573514,0.0001605582,0.0004924133,0.00006996502,0.00002752031,0.000004295882,0.0001395335,0.0001000989,0.00001282481],"category_scores_gemma":[0.0001312638,0.00009609116,0.0001591786,0.0003167804,0.00007048727,0.00002957079,0.00004882726,0.0002035725,0.000003427191],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005692197,"about_ca_system_score_gemma":0.0005869697,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008750643,"about_ca_topic_score_gemma":0.0000102673,"domain_scores_codex":[0.9984158,0.00009798075,0.0006603044,0.0002555204,0.0003476419,0.0002228057],"domain_scores_gemma":[0.9992497,0.00005272044,0.0002242235,0.0003326873,0.00006266788,0.00007797615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.06082346,0.0259939,0.7317359,0.0002941746,0.004518119,0.002614352,0.003166585,0.00018426,0.1212211,0.000987631,0.0007387442,0.04772179],"study_design_scores_gemma":[0.1521902,0.002938847,0.0459081,0.000437762,0.001124327,0.00004865158,0.00006052506,0.00005666213,0.7951244,0.0001013723,0.001764612,0.00024461],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996565,0.0002281316,0.00003484509,0.0006711077,0.00005378675,0.001028472,0.000004145172,0.00001570581,0.001398798],"genre_scores_gemma":[0.9940372,0.00002398615,0.005045888,0.00009341443,0.00006964357,0.00002761375,0.00001553426,0.00001501122,0.0006717169],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6858278,"threshold_uncertainty_score":0.3918484,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2196190612","doi":"10.1016/s1473-3099(15)00348-5","title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","year":2015,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":304,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Tenofovir alafenamide; Medicine; Emtricitabine; Cobicistat; Regimen; Tolerability; Internal medicine; Rilpivirine; Clinical endpoint; Elvitegravir; Pharmacology; Viral load; Adverse effect; Gastroenterology; Clinical trial; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","authors":[{"name":"Anthony Mills","is_ca":false},{"name":"José Ramón Arribas","is_ca":false},{"name":"Jaime Andrade‐Villanueva","is_ca":false},{"name":"Giovanni DiPerri","is_ca":false},{"name":"Jan van Lunzen","is_ca":false},{"name":"Ellen Koenig","is_ca":false},{"name":"Richard Elion","is_ca":false},{"name":"Matthias Cavassini","is_ca":false},{"name":"José Valdez Madruga","is_ca":false},{"name":"Jason Brunetta","is_ca":true},{"name":"David Shamblaw","is_ca":false},{"name":"Edwin DeJesus","is_ca":false},{"name":"Chloe Orkin","is_ca":false},{"name":"David A. Wohl","is_ca":false},{"name":"Indira Brar","is_ca":false},{"name":"Jeffrey L. Stephens","is_ca":false},{"name":"Pierre-Marie Girard","is_ca":false},{"name":"Gregory Huhn","is_ca":false},{"name":"Andrew Plummer","is_ca":false},{"name":"Ya-Pei Liu","is_ca":false},{"name":"Andrew Cheng","is_ca":false},{"name":"Scott McCallister","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03418472364530394,"gpt":0.3281702941383671,"spread":0.2939855704930631,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006367273,0.0006378489,0.001862417,0.0002172533,0.0003862504,0.0002450227,0.0003725598,0.0001114646,0.00004196561],"category_scores_gemma":[0.0008327367,0.0003728653,0.0001540009,0.0005011079,0.00009267284,0.000441912,0.0002614826,0.0003615547,0.00007313955],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004068443,"about_ca_system_score_gemma":0.0004620568,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001287961,"about_ca_topic_score_gemma":0.002350112,"domain_scores_codex":[0.9966986,0.0004248232,0.0006818358,0.000893032,0.0004917333,0.0008099689],"domain_scores_gemma":[0.997323,0.0007158697,0.0003380553,0.0007922732,0.0002834269,0.0005473778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3426532,0.01344004,0.633047,0.00006292104,0.001233563,0.0002718035,0.003827605,0.0001702244,0.0005277676,0.000008667177,0.001197031,0.003560177],"study_design_scores_gemma":[0.7542943,0.007473506,0.2300211,0.0003710836,0.00182577,0.00002259546,0.001131637,0.003069815,0.0002307845,0.0002051355,0.0006643902,0.0006898589],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802371,0.0001266384,0.0007753416,0.001712804,0.0002041594,0.01562481,0.0003142978,0.0002892093,0.0007156743],"genre_scores_gemma":[0.9928192,0.00005794954,0.000546638,0.0007479205,0.000445878,0.004481241,0.0002939941,0.00006976868,0.0005373409],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4116412,"threshold_uncertainty_score":0.9998723,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2129710521","doi":"10.1001/jama.285.9.1155","title":"Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>","year":2001,"lang":"id","type":"article","venue":"JAMA","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":279,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Lamivudine; Indinavir; Abacavir; Zidovudine; Medicine; Regimen; Virology; Placebo; Efavirenz; Internal medicine; Stavudine; Gastroenterology; Viral load; Human immunodeficiency virus (HIV); Viral disease; Virus; Antiretroviral therapy","authors":[{"name":"Schlomo Staszewski","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01464476412462442,"gpt":0.2650518327198785,"spread":0.2504070685952541,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.004026749,0.003025422,0.006683233,0.002590594,0.0006511416,0.0004847176,0.001421393,0.001829969,0.006749501],"category_scores_gemma":[0.005079828,0.002660439,0.001804124,0.004801676,0.001204144,0.001368022,0.0008884683,0.002472426,0.01178778],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002169098,"about_ca_system_score_gemma":0.001167456,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003451106,"about_ca_topic_score_gemma":0.000410466,"domain_scores_codex":[0.9834817,0.001704268,0.004837287,0.003342799,0.002909146,0.003724791],"domain_scores_gemma":[0.9906755,0.002387448,0.002138613,0.002390636,0.001049379,0.001358426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7336872,0.0090476,0.1195292,0.00151923,0.004477779,0.01082547,0.004814724,0.0000289208,0.008859037,0.001183964,0.08526917,0.0207577],"study_design_scores_gemma":[0.8909482,0.002833389,0.03390301,0.005616727,0.002940394,0.0003873832,0.0004010393,0.002667011,0.003754742,0.0002073466,0.05312986,0.003210955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9157915,0.006950825,0.0002648148,0.01131889,0.003904757,0.01086314,0.0003875987,0.0008039657,0.04971456],"genre_scores_gemma":[0.8240378,0.01637584,0.000800489,0.0006889595,0.003030106,0.001088333,0.002079389,0.0004569763,0.1514421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1572609,"threshold_uncertainty_score":0.9998289,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3000709627","doi":"10.1093/cid/ciz1243","title":"Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study","year":2020,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"ViiV Healthcare","keywords":"Tenofovir alafenamide; Medicine; Dolutegravir; Regimen; Lamivudine; Adverse effect; Internal medicine; Population; Viral load; Pharmacology; Human immunodeficiency virus (HIV); Immunology; Virus; Hepatitis B virus","authors":[{"name":"Jean van Wyk","is_ca":false},{"name":"Faïza Ajana","is_ca":false},{"name":"Fiona Bisshop","is_ca":false},{"name":"Stéphane De Wit","is_ca":false},{"name":"Olayemi Osiyemi","is_ca":false},{"name":"Joaquín Portilla","is_ca":false},{"name":"Jean‐Pierre Routy","is_ca":true},{"name":"Christoph Wyen","is_ca":false},{"name":"Mounir Ait‐Khaled","is_ca":false},{"name":"Maria Cláudia Nascimento","is_ca":false},{"name":"Keith A. Pappa","is_ca":false},{"name":"Ruolan Wang","is_ca":false},{"name":"Jonathan Wright","is_ca":false},{"name":"Allan R. Tenorio","is_ca":false},{"name":"Brian Wynne","is_ca":false},{"name":"Michael Aboud","is_ca":false},{"name":"Martin Gartland","is_ca":false},{"name":"Kimberly Y. Smith","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02162887313150714,"gpt":0.3442438337001976,"spread":0.3226149605686905,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001320489,0.0004310852,0.002091783,0.0001929061,0.0001554131,0.00002704317,0.0001754944,0.00009452152,0.0000310705],"category_scores_gemma":[0.005092445,0.0002708957,0.0002591589,0.0005313528,0.0002666234,0.0001286554,0.0001751206,0.0003079167,0.00000329177],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008632955,"about_ca_system_score_gemma":0.0002640499,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001819551,"about_ca_topic_score_gemma":0.0002741447,"domain_scores_codex":[0.9963322,0.000532145,0.001592531,0.0007902379,0.0003307415,0.0004221672],"domain_scores_gemma":[0.9948297,0.003414586,0.0006841899,0.0004341176,0.0002760606,0.0003613561],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3440526,0.01268719,0.6305091,0.0005452851,0.0005881953,0.0001523521,0.005048356,0.0001015555,0.001510226,0.00003787719,0.0002733703,0.004493905],"study_design_scores_gemma":[0.553932,0.01325871,0.4190924,0.00585304,0.002163607,0.000008396897,0.001411286,0.002839854,0.0005507184,0.0000513855,0.0001488772,0.0006896767],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926733,0.0004361616,0.000491711,0.0007449918,0.00008106622,0.005343012,0.00005440701,0.0001106444,0.00006471189],"genre_scores_gemma":[0.9985387,0.0001851404,0.0004859137,0.0002399464,0.00006396227,0.0002445791,0.00004546468,0.00004645676,0.0001497852],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2114167,"threshold_uncertainty_score":0.9999743,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3196876339","doi":"10.1177/135965350801302s03","title":"The World Health Organization's global strategy for prevention and assessment of HIV drug resistance","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Regimen; Medicine; Developing country; Public health; Resource (disambiguation); Human immunodeficiency virus (HIV); Environmental health; Antiretroviral therapy; Economic growth; Viral load; Family medicine; Nursing; Surgery; Computer science","authors":[{"name":"Diane Bennett","is_ca":false},{"name":"Silvia Bertagnolio","is_ca":false},{"name":"Donald Sutherland","is_ca":true},{"name":"Charles F. Gilks","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02974505837060322,"gpt":0.3470594945262849,"spread":0.3173144361556817,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001523203,0.00009137986,0.0001768631,0.00002362612,0.0002407067,0.00001092288,0.00003918932,0.00001547563,0.000009461793],"category_scores_gemma":[0.00000686067,0.00005893843,0.00003572284,0.000239124,0.0000660592,0.00005430143,0.0000077228,0.00003684738,0.000001379484],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006353064,"about_ca_system_score_gemma":0.0002585906,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003853634,"about_ca_topic_score_gemma":0.0001614294,"domain_scores_codex":[0.9993418,0.00004444494,0.0001965425,0.0001370979,0.0001413257,0.0001387464],"domain_scores_gemma":[0.999604,0.00005238261,0.0001101175,0.0001149879,0.00008562979,0.00003287174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005798895,0.0008649944,0.7989892,0.0001202691,0.0004955463,0.00001195325,0.0009194648,0.000001598313,0.0004479878,0.039888,0.09298912,0.06469192],"study_design_scores_gemma":[0.007506915,0.0003272407,0.8236308,0.0002022522,0.00003807761,0.00001232442,0.0002853517,0.00006557441,0.006024171,0.002835782,0.1588524,0.0002191498],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9527509,0.003670816,0.002189381,0.03439241,0.0000994224,0.001683837,0.00002569838,0.0000587534,0.005128834],"genre_scores_gemma":[0.9209571,0.003748309,0.004852351,0.0001050746,0.00003332283,0.0000188714,0.00005926292,0.00001055025,0.07021517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06586331,"threshold_uncertainty_score":0.2403439,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045871034","doi":"10.1016/s1473-3099(09)70136-7","title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","year":2009,"lang":"en","type":"review","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver","funders":"Seventh Framework Programme","keywords":"Lamivudine; Reverse transcriptase; Medicine; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Drug resistance; Nucleoside analogue; Didanosine; Virology; Nucleoside; Viral load; Zidovudine; Resistance mutation; Internal medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral disease; Biology; Virus; RNA","authors":[{"name":"Ravindra K. Gupta","is_ca":false},{"name":"Andrew Hill","is_ca":false},{"name":"Anthony Sawyer","is_ca":false},{"name":"Alessandro Cozzi‐Lepri","is_ca":false},{"name":"Viktor von Wyl","is_ca":false},{"name":"Sabine Yerly","is_ca":false},{"name":"Viviane D. Lima","is_ca":true},{"name":"Huldrych F. Günthard","is_ca":false},{"name":"Charles F. Gilks","is_ca":false},{"name":"Deenan Pillay","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07017780613493417,"gpt":0.3493240932979655,"spread":0.2791462871630313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003025838,0.000784765,0.008376109,0.000399984,0.0001454641,0.00006597769,0.0001509718,0.000147788,0.00002367796],"category_scores_gemma":[0.0002996505,0.0003513557,0.0006757918,0.001687661,0.00008547214,0.00008013905,0.00005395178,0.0002867896,0.00001018857],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002128376,"about_ca_system_score_gemma":0.0001023415,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004566952,"about_ca_topic_score_gemma":0.000176915,"domain_scores_codex":[0.9970433,0.0005333416,0.0009747627,0.0007052373,0.0003474003,0.0003960139],"domain_scores_gemma":[0.9979163,0.0004732753,0.0004983387,0.000698209,0.0002023401,0.0002115199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001301913,0.001237267,0.02724947,0.6818315,0.2746819,0.0004777739,0.0004025002,0.00002310649,1.044042e-7,0.00007673976,0.0009936828,0.01172406],"study_design_scores_gemma":[0.002687736,0.0008778569,0.007857891,0.1242004,0.8584968,0.00007163829,0.00002074321,0.000003851383,5.861936e-7,0.00003929647,0.005018757,0.0007245186],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002727289,0.9899651,0.00001237847,0.00183649,0.000009192332,0.005017053,0.0001822135,0.0001603688,0.00008994857],"genre_scores_gemma":[0.006739587,0.9898114,0.00006700704,0.000695703,0.00009172883,0.001556431,0.0001788241,0.00004387347,0.0008155071],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5838149,"threshold_uncertainty_score":0.9998938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157533742","doi":"10.1086/497610","title":"Pharmacogenetics of Long‐Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study","year":2005,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":252,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; ACT Government; School of Medicine, Vanderbilt University; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases","keywords":"Efavirenz; Nelfinavir; CYP2B6; CYP2C19; Medicine; Population; Pharmacology; Pharmacogenetics; Abacavir; Internal medicine; Virology; Biology; Viral load; Genotype; Virus; CYP3A4; Genetics; Cytochrome P450; Antiretroviral therapy","authors":[{"name":"David W. Haas","is_ca":false},{"name":"Laura Smeaton","is_ca":false},{"name":"Robert W. Shafer","is_ca":false},{"name":"Gregory K. Robbins","is_ca":false},{"name":"Gene D. Morse","is_ca":false},{"name":"Line Labbé","is_ca":true},{"name":"G. Wilkinson","is_ca":false},{"name":"David B. Clifford","is_ca":false},{"name":"Richard T. D’Aquila","is_ca":false},{"name":"Victor De Gruttola","is_ca":false},{"name":"Richard B. Pollard","is_ca":false},{"name":"Thomas C. Merigan","is_ca":false},{"name":"Martin Hirsch","is_ca":false},{"name":"Alfred L. George","is_ca":false},{"name":"John P. Donahue","is_ca":false},{"name":"Richard B. Kim","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07383009193538165,"gpt":0.4336922300749886,"spread":0.359862138139607,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003518363,0.0002354342,0.0010063,0.0002670291,0.0001406422,0.00003285342,0.0001452262,0.00005415435,0.0000647769],"category_scores_gemma":[0.002960189,0.0001304564,0.0002572668,0.0002244441,0.0001287842,0.0001575787,0.00006604042,0.0002277242,0.000006008341],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008850145,"about_ca_system_score_gemma":0.0003513644,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001390789,"about_ca_topic_score_gemma":0.00003668147,"domain_scores_codex":[0.9959694,0.001694424,0.001461799,0.0001737707,0.0004515933,0.0002490048],"domain_scores_gemma":[0.9965348,0.001517817,0.0007598233,0.000262633,0.0003301565,0.0005947606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01932227,0.003539813,0.9046345,0.00002459506,0.001000032,0.0002484384,0.001735367,0.000008964844,0.0004222751,0.000006061303,0.0003588672,0.0686988],"study_design_scores_gemma":[0.01692895,0.03466234,0.9404801,0.0002933572,0.004578058,0.0005577335,0.001513152,0.00002250061,0.0006103336,0.00001323497,0.0001477549,0.0001924586],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975536,0.0008405973,0.00009962341,0.0004610635,0.0001941309,0.0007685066,0.00002043184,0.00002862646,0.00003338137],"genre_scores_gemma":[0.9972492,0.0009800269,0.0002703151,0.000477605,0.0006131887,0.000009714094,0.000003906775,0.0000271779,0.0003688065],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06850635,"threshold_uncertainty_score":0.5319856,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2057925552","doi":"10.1128/jvi.06591-11","title":"Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir","year":2011,"lang":"en","type":"article","venue":"Journal of Virology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Merck; Jewish General Hospital; Canadian Foundation for AIDS Research; Gilead Sciences","keywords":"Integrase; Dolutegravir; Biology; Integrase inhibitor; Mutagenesis; Mutation; DNA; Raltegravir; Virology; Viral replication; Reverse transcriptase; Genetics; Molecular biology; Virus; Gene; Viral load; Polymerase chain reaction","authors":[{"name":"Peter K. Quashie","is_ca":true},{"name":"Thibault Mésplède","is_ca":true},{"name":"Ying-Shan Han","is_ca":true},{"name":"Maureen Oliveira","is_ca":true},{"name":"Diane N. Singhroy","is_ca":true},{"name":"Tamio Fujiwara","is_ca":false},{"name":"Mark Underwood","is_ca":false},{"name":"Mark A. Wainberg","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03907600993030807,"gpt":0.2449276465907511,"spread":0.205851636660443,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004452833,0.0001411405,0.0003070479,0.0002030718,0.00004815296,0.000008952673,0.0001204496,0.0001034333,0.0002237673],"category_scores_gemma":[0.00005378472,0.00007483653,0.0001118049,0.0001902931,0.00008077644,0.0001298845,0.00001033933,0.0002820491,0.000006651397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009452479,"about_ca_system_score_gemma":0.0001754171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006782399,"about_ca_topic_score_gemma":0.001142462,"domain_scores_codex":[0.9987743,0.0001808277,0.0005538286,0.0001267049,0.0002179302,0.0001464388],"domain_scores_gemma":[0.9993713,0.00004333726,0.000204462,0.0001529947,0.0001564664,0.00007136357],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003342064,0.0006679144,0.02030493,0.00007287245,0.0003318666,0.000146492,0.02016681,0.00001021108,0.9493687,0.0007097558,0.00140405,0.003474361],"study_design_scores_gemma":[0.005332456,0.0005994936,0.3282711,0.0003588601,0.0002749983,0.0001705225,0.001404175,0.00006657435,0.6607102,0.0002213845,0.002428749,0.0001614648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894151,0.00004428078,0.003601722,0.005970075,0.0003372045,0.0004013919,0.00003837719,0.000003522176,0.0001883229],"genre_scores_gemma":[0.997609,0.00003922843,0.000454273,0.0005445627,0.0001108232,0.00001361761,0.00003734193,0.00001252551,0.001178634],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3079662,"threshold_uncertainty_score":0.3051745,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2025935798","doi":"10.1371/journal.pmed.1001810","title":"Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis","year":2015,"lang":"en","type":"review","venue":"PLoS Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AIDS Vancouver; Simon Fraser University; Public Health Agency of Canada","funders":"U.S. Public Health Service; National Institutes of Health; Biotechnology and Biological Sciences Research Council; World Health Organization; National Institute of Allergy and Infectious Diseases; Bill and Melinda Gates Foundation","keywords":"Drug resistance; Odds ratio; Molecular epidemiology; GenBank; Epidemiology; Virology; Medicine; Genotype; Demography; Biology; Genetics; Internal medicine","authors":[{"name":"Soo‐Yon Rhee","is_ca":false},{"name":"José Luís Blanco","is_ca":false},{"name":"Michael R. Jordan","is_ca":false},{"name":"Jonathan Taylor","is_ca":false},{"name":"Philippe Lemey","is_ca":false},{"name":"Vici Varghese","is_ca":false},{"name":"Raph L Hamers","is_ca":false},{"name":"Silvia Bertagnolio","is_ca":false},{"name":"Tobias F. Rinke de Wit","is_ca":false},{"name":"Avelin F. Aghokeng","is_ca":false},{"name":"Jan Albert","is_ca":false},{"name":"Radko Avi","is_ca":false},{"name":"Santiago Ávila‐Ríos","is_ca":false},{"name":"Pascal Bessong","is_ca":false},{"name":"James Brooks","is_ca":true},{"name":"Charles A. Boucher","is_ca":false},{"name":"Zabrina L. Brumme","is_ca":true},{"name":"Michael P. Busch","is_ca":false},{"name":"Hermann Bussmann","is_ca":false},{"name":"Marie‐Laure Chaix","is_ca":false},{"name":"Bum Sik Chin","is_ca":false},{"name":"Toni Thomas d’Aquin","is_ca":false},{"name":"Cillian De Gascun","is_ca":false},{"name":"Anne Derache","is_ca":false},{"name":"Diane Descamps","is_ca":false},{"name":"Alaka Deshpande","is_ca":false},{"name":"Cyrille F. Djoko","is_ca":false},{"name":"Susan H. Eshleman","is_ca":false},{"name":"Hervé Fleury","is_ca":false},{"name":"Pierre Frange","is_ca":false},{"name":"Seiichiro Fujisaki","is_ca":false},{"name":"P. Richard Harrigan","is_ca":true},{"name":"Junko Hattori","is_ca":false},{"name":"África Holguín","is_ca":false},{"name":"Gillian Hunt","is_ca":false},{"name":"Hiroshi Ichimura","is_ca":false},{"name":"Pontiano Kaleebu","is_ca":false},{"name":"David Katzenstein","is_ca":false},{"name":"Sasisopin Kiertiburanakul","is_ca":false},{"name":"Jérôme H. Kim","is_ca":false},{"name":"Sung Soon Kim","is_ca":false},{"name":"Yanpeng Li","is_ca":false},{"name":"Irja Lutsar","is_ca":false},{"name":"Lynn Morris","is_ca":false},{"name":"Nicaise Ndembi","is_ca":false},{"name":"Kee Peng Ng","is_ca":false},{"name":"Ramesh Paranjape","is_ca":false},{"name":"Martine Peeters","is_ca":false},{"name":"Mario Poljak","is_ca":false},{"name":"Matt A. Price","is_ca":false},{"name":"Manon Ragonnet‐Cronin","is_ca":false},{"name":"Gustavo Reyes‐Terán","is_ca":false},{"name":"Morgane Rolland","is_ca":false},{"name":"Sunee Sirivichayakul","is_ca":false},{"name":"Davey M. Smith","is_ca":false},{"name":"Marcelo A. Soares","is_ca":false},{"name":"Vincent Soriano","is_ca":false},{"name":"Deogratius Ssemwanga","is_ca":false},{"name":"Maja Stanojević","is_ca":false},{"name":"Mariane A. Stefani","is_ca":false},{"name":"Wataru Sugiura","is_ca":false},{"name":"Somnuek Sungkanuparph","is_ca":false},{"name":"Amílcar Tanuri","is_ca":false},{"name":"Kok Keng Tee","is_ca":false},{"name":"Hong-Ha M. Truong","is_ca":false},{"name":"David van de Vijver","is_ca":false},{"name":"Nicole Vidal","is_ca":false},{"name":"Chunfu Yang","is_ca":false},{"name":"Rongge Yang","is_ca":false},{"name":"Gonzalo Yebra","is_ca":false},{"name":"John P. A. Ioannidis","is_ca":false},{"name":"Anne‐Mieke Vandamme","is_ca":false},{"name":"Robert W. Shafer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2218405918892829,"gpt":0.3721868621797614,"spread":0.1503462702904785,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001983364,0.000663638,0.00614684,0.001803813,0.0000607008,0.000008262768,0.0001988944,0.0002807945,0.00008579074],"category_scores_gemma":[0.0001718204,0.0003430382,0.0004550961,0.001616249,0.0005387072,0.00004795191,0.00005366126,0.0004256067,7.541737e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000365876,"about_ca_system_score_gemma":0.0001262247,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008051349,"about_ca_topic_score_gemma":0.0002792619,"domain_scores_codex":[0.9952368,0.001374573,0.00148652,0.0008277241,0.0006822814,0.0003921428],"domain_scores_gemma":[0.9977912,0.0005318527,0.0006159781,0.000611103,0.0001114675,0.0003384176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.000272666,0.001677833,0.01670423,0.02456921,0.4371172,0.003251492,0.02920136,0.000001378112,0.00001744606,0.002389636,0.002793042,0.4820045],"study_design_scores_gemma":[0.003349048,0.0006259584,0.002835342,0.002525454,0.9232446,0.000296501,0.0009688593,0.0000397193,0.000005275224,0.003136344,0.0622641,0.0007087908],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004966103,0.9888862,0.000103929,0.004658076,0.0000172803,0.001053852,0.0002027399,0.00001853871,0.00009332319],"genre_scores_gemma":[0.01319601,0.975864,0.007286698,0.0004028699,0.00003167902,0.0003569906,0.002046701,0.00005507185,0.0007600056],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4861274,"threshold_uncertainty_score":0.9999022,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1968328048","doi":"10.1016/j.tips.2009.10.001","title":"The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters","year":2009,"lang":"en","type":"review","venue":"Trends in Pharmacological Sciences","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Drug; Pharmacology; Antiretroviral drug; ATP-binding cassette transporter; Drug interaction; Efflux; Pharmacokinetics; Transporter; Human immunodeficiency virus (HIV); Drug metabolism; Antiretroviral therapy; Medicine; Virology; Biology; Viral load; Biochemistry","authors":[{"name":"Olena Kis","is_ca":true},{"name":"Kevin R. Robillard","is_ca":true},{"name":"Gary N. Y. Chan","is_ca":true},{"name":"Reina Bendayan","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08393546633828616,"gpt":0.4171650216645466,"spread":0.3332295553262604,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005364264,0.0002465191,0.001070071,0.0003271324,0.0001447358,0.00001554057,0.000261641,0.00004201004,0.0002726171],"category_scores_gemma":[0.00001322863,0.0001192854,0.0002401793,0.0007801198,0.001159094,0.00007646362,0.00003575128,0.0002520618,0.000002315675],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005900418,"about_ca_system_score_gemma":0.0001068269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003192534,"about_ca_topic_score_gemma":0.00003962445,"domain_scores_codex":[0.9982887,0.0001440444,0.0006904667,0.0003083135,0.0003004675,0.0002680243],"domain_scores_gemma":[0.9990897,0.0004246497,0.0003021314,0.00008125725,0.00002411549,0.00007814444],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000336904,0.0002285959,0.001353239,0.0003142408,0.000103521,0.00001390799,0.0003457862,4.270777e-7,0.000009432334,0.0003833006,0.0006729896,0.9965408],"study_design_scores_gemma":[0.001168169,0.0004438617,0.004145849,0.003893033,0.00150875,0.00005298067,0.001023206,0.00007133907,0.0001472483,0.0006019879,0.986603,0.0003405911],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.008949215,0.9796591,2.836107e-7,0.0006159544,0.0001305537,0.0003066291,0.00002489085,0.00001904126,0.01029427],"genre_scores_gemma":[0.0657215,0.9309793,0.0002664537,0.00002707312,0.0000392574,0.00003539756,0.00002301726,0.000004791296,0.002903192],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9962003,"threshold_uncertainty_score":0.4864316,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1995559092","doi":"10.1097/01.aids.0000232228.88511.0b","title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture","year":2006,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Didanosine; Lamivudine; Resistance mutation; Virology; Zidovudine; Abacavir; Biology; Reverse transcriptase; Drug resistance; Genotype; Stavudine; Genotyping; Reverse-transcriptase inhibitor; Virus; Sida; Genetics; Viral disease; Polymerase chain reaction; Gene; Hepatitis B virus","authors":[{"name":"Bluma Brenner","is_ca":true},{"name":"Maureen Oliveira","is_ca":true},{"name":"Florence Doualla‐Bell","is_ca":true},{"name":"Daniela Moïsi","is_ca":true},{"name":"Michel Ntemgwa","is_ca":true},{"name":"Fernando Frankel","is_ca":true},{"name":"Max Essex","is_ca":false},{"name":"Mark A. Wainberg","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01021666569478998,"gpt":0.2445065241397908,"spread":0.2342898584450008,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001371015,0.0002102444,0.0002974448,0.0001877112,0.00006184971,0.0000194193,0.0000988823,0.00009774022,0.0001428627],"category_scores_gemma":[0.00004694304,0.0001646535,0.0000489064,0.0007684422,0.00002733593,0.00007006997,0.00003905938,0.0001303785,0.001204563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000183254,"about_ca_system_score_gemma":0.0001734251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005016036,"about_ca_topic_score_gemma":0.0002471476,"domain_scores_codex":[0.998736,0.00003059179,0.000299416,0.0003322323,0.000255565,0.0003461602],"domain_scores_gemma":[0.9994622,0.00003527705,0.00004542776,0.0002474371,0.00009450343,0.0001151744],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002920802,0.0004502706,0.690204,0.00007749756,0.00004241896,0.0003733975,0.00143477,0.000005457315,0.009523537,0.0007464304,0.295864,0.000986158],"study_design_scores_gemma":[0.002456817,0.0001099654,0.1780155,0.0001673075,0.00005591323,0.000007799673,0.000237883,0.000001581687,0.05456821,0.0002123134,0.7638455,0.0003212028],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9037222,0.001483532,0.0001909032,0.003396545,0.0001377338,0.0006188191,0.000018623,0.0001394448,0.09029216],"genre_scores_gemma":[0.7349338,0.00004059517,0.02318927,0.001134522,0.0001148906,0.0000516478,0.00007676263,0.00002928226,0.2404293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5121884,"threshold_uncertainty_score":0.9995731,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151647473","doi":"10.1086/499364","title":"Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study","year":2006,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; University of California, San Diego; National Institute of Neurological Disorders and Stroke; University of Pittsburgh; University of Washington; Case Western Reserve University; University of Minnesota; Pfizer; Northwestern University; Biogen; University of Rochester; University of Miami; York University; Bristol-Myers Squibb; Quest Diagnostics; University of Pennsylvania; Gilead Sciences; Vanderbilt University; National Institutes of Health; Ohio State University; ACT Government; University of Southern California; Emory University; Brigham and Women's Hospital; GlaxoSmithKline","keywords":"Efavirenz; Discontinuation; Medicine; CYP2B6; Internal medicine; Interquartile range; Genotype; Gastroenterology; Pharmacogenetics; Pharmacokinetics; Population; Pharmacology; Viral load; Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Biology; Genetics; Cytochrome P450; CYP3A4","authors":[{"name":"Heather J. Ribaudo","is_ca":false},{"name":"David W. Haas","is_ca":false},{"name":"C. Tierney","is_ca":false},{"name":"Richard B. Kim","is_ca":false},{"name":"G. Wilkinson","is_ca":false},{"name":"Roy M. Gulick","is_ca":false},{"name":"David B. Clifford","is_ca":false},{"name":"Catia Marzolini","is_ca":false},{"name":"Courtney V. Fletcher","is_ca":false},{"name":"Karen T. Tashima","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Edward P. Acosta","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08505330597271046,"gpt":0.4501052160299698,"spread":0.3650519100572593,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001489817,0.000436889,0.001828594,0.0001430473,0.0001014204,0.00004594028,0.00009773749,0.0002085622,0.0003743397],"category_scores_gemma":[0.00113665,0.0003054234,0.001049439,0.000248504,0.0002787548,0.0001307984,0.00005663102,0.0001944322,0.00008202794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009953437,"about_ca_system_score_gemma":0.0002493139,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004943356,"about_ca_topic_score_gemma":0.0002779023,"domain_scores_codex":[0.9934435,0.001876286,0.003140305,0.0007547251,0.0004490507,0.0003361141],"domain_scores_gemma":[0.9960441,0.001883929,0.000638462,0.0006063706,0.000285047,0.0005420744],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001402923,0.0460721,0.8725857,0.00001996525,0.00121138,0.000175488,0.00009715332,0.000005986692,0.000008902236,0.00003579814,0.0006445397,0.07774013],"study_design_scores_gemma":[0.02533477,0.01369458,0.9537842,0.00007676599,0.004742079,0.000005248188,0.0001901391,0.00007988512,0.0001018582,0.0001055773,0.001585791,0.000299132],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955513,0.0005270439,0.000051656,0.0001749704,0.0007811693,0.00219725,0.0001476272,0.000172546,0.0003964103],"genre_scores_gemma":[0.9949769,0.0004082318,0.0001871926,0.0001552227,0.001626746,0.0005170656,0.0003478867,0.00005042485,0.001730275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08119852,"threshold_uncertainty_score":0.9999398,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2053792903","doi":"10.1038/nsmb.1540","title":"Nucleic acid polymerases use a general acid for nucleotidyl transfer","year":2009,"lang":"en","type":"article","venue":"Nature Structural & Molecular Biology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Institutes of Health","keywords":"Chemistry; Polymerase; Pyrophosphate; Deprotonation; Nucleic acid; Active site; DNA polymerase; Protonation; Stereochemistry; Biochemistry; DNA polymerase beta; Leaving group; Enzyme; DNA; Catalysis; Base excision repair; DNA repair; Organic chemistry","authors":[{"name":"Christian Castro","is_ca":false},{"name":"Eric D. Smidansky","is_ca":false},{"name":"Jamie J. Arnold","is_ca":false},{"name":"Kenneth R. Maksimchuk","is_ca":false},{"name":"Ibrahim M. Moustafa","is_ca":false},{"name":"Akira Uchida","is_ca":false},{"name":"Matthias Götte","is_ca":true},{"name":"William H. Konigsberg","is_ca":false},{"name":"Craig E. Cameron","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007258418535612243,"gpt":0.3003279623161461,"spread":0.2930695437805338,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004585567,0.0003814608,0.0004954824,0.0001615034,0.0001262148,0.0000286914,0.0001440471,0.0005741215,0.0001339929],"category_scores_gemma":[0.00007336483,0.000274342,0.0003138289,0.0001935283,0.00009026194,0.00007525236,0.00001888216,0.0004158834,0.00001183077],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007312342,"about_ca_system_score_gemma":0.00008443575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000581429,"about_ca_topic_score_gemma":0.000005586071,"domain_scores_codex":[0.9984249,0.00005598417,0.000287322,0.0005388365,0.0001508305,0.0005421009],"domain_scores_gemma":[0.999332,0.00002105397,0.0000401869,0.0003069239,0.0001103783,0.0001895355],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005423102,0.00004625291,0.001442717,0.00001590359,0.0002949753,0.0001467577,0.0001255642,7.779664e-7,0.9649449,0.01570075,0.001096045,0.01564303],"study_design_scores_gemma":[0.005320414,0.0009891815,0.02191694,0.0000392091,0.0003850011,0.0003745012,0.00002126639,0.0001045398,0.9499341,0.003027514,0.01733074,0.0005566496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848839,0.002814021,0.0009722714,0.009779221,0.0003289768,0.0008185961,0.0001019947,0.0001244701,0.0001765444],"genre_scores_gemma":[0.9797192,0.00003028521,0.01201052,0.006251528,0.0002125407,0.00002438213,0.000768592,0.00003520711,0.0009476986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02047423,"threshold_uncertainty_score":0.9999709,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2252811454","doi":"10.1097/qai.0000000000000790","title":"Brief Report","year":2015,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"Cilag; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Dolutegravir; Abacavir; Lamivudine; Emtricitabine; Efavirenz; Medicine; Virology; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Chronic hepatitis; Virus","authors":[{"name":"Sharon Walmsley","is_ca":true},{"name":"Axel Baumgarten","is_ca":false},{"name":"Juan Berenguer","is_ca":false},{"name":"Franco Felizarta","is_ca":false},{"name":"Éric Florence","is_ca":false},{"name":"Marie-Aude Khuong-Josses","is_ca":false},{"name":"J Michael Kilby","is_ca":false},{"name":"Thomas A. Lutz","is_ca":false},{"name":"Daniel Podzamczer","is_ca":false},{"name":"Joaquín Portilla","is_ca":false},{"name":"Norman Roth","is_ca":false},{"name":"Deborah Jean Lee Wong","is_ca":false},{"name":"Catherine Granier","is_ca":false},{"name":"Brian Wynne","is_ca":false},{"name":"Keith A. Pappa","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0341467119659951,"gpt":0.2919896861536674,"spread":0.2578429741876723,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001618221,0.0002482301,0.0007819763,0.0005718302,0.00008877603,0.00004563323,0.0002352915,0.0001036976,0.00008910875],"category_scores_gemma":[0.0008873758,0.0001801672,0.000344395,0.0007570109,0.000129448,0.00032787,0.00007302401,0.000120247,0.0002309697],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002406041,"about_ca_system_score_gemma":0.0007990472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001088568,"about_ca_topic_score_gemma":4.430339e-7,"domain_scores_codex":[0.9970379,0.00006290207,0.001256707,0.0002264416,0.001006997,0.0004090927],"domain_scores_gemma":[0.9978256,0.00008042291,0.0006614586,0.0004372531,0.0006528234,0.0003423943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"case_report","study_design_scores_codex":[0.003064641,0.007606212,0.4851923,0.0005588303,0.004268163,0.1794304,0.01765534,0.0001640968,0.02464718,0.002047118,0.2181769,0.05718875],"study_design_scores_gemma":[0.02569609,0.006711659,0.3405913,0.001956734,0.002294933,0.4120869,0.009167519,0.0001861847,0.02393843,0.002678575,0.1730893,0.001602395],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804972,0.005899683,0.0003334971,0.003739594,0.001217126,0.0002269403,0.000002162895,0.00008325336,0.008000545],"genre_scores_gemma":[0.9641286,0.0001807779,0.004756019,0.00006685054,0.0001073494,0.000005205176,0.00001551791,0.00004330208,0.03069645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2326565,"threshold_uncertainty_score":0.7347007,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121720236","doi":"10.1056/nejmra1004180","title":"Development of Antiretroviral Drug Resistance","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Human immunodeficiency virus (HIV); Drug resistance; Antiretroviral drug; ANTIRETROVIRAL AGENTS; Drug; HIV drug resistance; Resistance (ecology); Virology; Antiretroviral therapy; Medicine; Computational biology; Biology; Pharmacology; Genetics; Viral load","authors":[{"name":"Mark A. Wainberg","is_ca":true},{"name":"Gerasimos J. Zaharatos","is_ca":true},{"name":"Bluma Brenner","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03104493270825844,"gpt":0.2620090213942288,"spread":0.2309640886859703,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007621833,0.0001559925,0.0005844517,0.0002559197,0.00003870692,0.000001783666,0.0001133271,0.00003884295,0.0004465282],"category_scores_gemma":[0.0001370087,0.00009424653,0.00007017795,0.0001891564,0.00009088376,0.00006768211,0.0000176868,0.0001914099,0.000009958627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006674942,"about_ca_system_score_gemma":0.0004934824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001034029,"about_ca_topic_score_gemma":0.00003931044,"domain_scores_codex":[0.9982767,0.00003543557,0.0008293446,0.0001094145,0.0005660597,0.0001830148],"domain_scores_gemma":[0.9988647,0.00005635869,0.0004332296,0.000143509,0.0002166405,0.0002855971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00941324,0.001115783,0.2286362,0.0005195501,0.001828254,0.002691046,0.130088,3.880229e-7,0.01550713,0.001577832,0.1371754,0.4714471],"study_design_scores_gemma":[0.132694,0.001457379,0.08941635,0.00426602,0.000940272,0.001139015,0.002367131,0.000003691034,0.06746602,0.0009666248,0.6989004,0.0003830944],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9714759,0.002234943,0.000724172,0.004682162,0.0004862812,0.0001561615,6.588655e-7,0.00001453036,0.02022518],"genre_scores_gemma":[0.911521,0.0001837962,0.06357523,0.0001142397,0.0007065391,8.166178e-7,0.000004628983,0.00001581508,0.023878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.561725,"threshold_uncertainty_score":0.4889171,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2510140996","doi":"10.1016/s2352-3018(16)30091-1","title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis","year":2016,"lang":"en","type":"review","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"World Health Organization","keywords":"Medicine; Efavirenz; Dolutegravir; Adverse effect; Meta-analysis; Odds ratio; Raltegravir; Viral load; Internal medicine; Indinavir; MEDLINE; Confidence interval; Antiretroviral therapy; Human immunodeficiency virus (HIV); Family medicine","authors":[{"name":"Steve Kanters","is_ca":true},{"name":"Marco Vitória","is_ca":false},{"name":"Meg Doherty","is_ca":false},{"name":"M. Eugenia Socías","is_ca":false},{"name":"Nathan Ford","is_ca":false},{"name":"Jamie I. Forrest","is_ca":true},{"name":"Evan Popoff","is_ca":false},{"name":"Nick Bansback","is_ca":true},{"name":"Sabin Nsanzimana","is_ca":false},{"name":"Kristian Thorlund","is_ca":false},{"name":"Edward J. Mills","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1560874485520365,"gpt":0.3874352813437313,"spread":0.2313478327916948,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007611809,0.0004451421,0.01035624,0.00007744649,0.0001352926,0.00001086528,0.0001215222,0.00007401517,0.00006682214],"category_scores_gemma":[0.00003584305,0.000141532,0.001465371,0.0004441051,0.00015524,0.00002104396,0.00002606878,0.00007523625,0.000006300361],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006081324,"about_ca_system_score_gemma":0.00005737799,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000558434,"about_ca_topic_score_gemma":0.00001351893,"domain_scores_codex":[0.9979544,0.0003764385,0.000989884,0.0002871712,0.0001853468,0.0002068076],"domain_scores_gemma":[0.9959772,0.002200591,0.0009436497,0.0007362133,0.000095346,0.00004696193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.0002781191,0.0003968117,0.0003559052,0.4063077,0.5681471,0.000002814297,0.0007129108,0.000003760742,2.884265e-8,0.0002255706,0.002732656,0.02083664],"study_design_scores_gemma":[0.001883515,0.0004298784,0.00006035675,0.0362648,0.6344219,0.00001552032,0.000005832605,0.00001492056,7.290745e-7,0.00001071236,0.3267549,0.0001369334],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001134882,0.9898083,0.0001961631,0.001908223,0.00002249024,0.007731807,0.0002206017,0.00001430103,0.00008682466],"genre_scores_gemma":[0.0001793637,0.994772,0.0001544071,0.00005661531,0.000148647,0.001096531,0.0001267622,0.0000200338,0.003445611],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3700429,"threshold_uncertainty_score":0.7079316,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135892517","doi":"10.1097/00002030-200106150-00003","title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals","year":2001,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"HIV Legal Network; St. Paul's Hospital","funders":"Institut National Du Cancer","keywords":"Nevirapine; Zidovudine; Medicine; Didanosine; Regimen; Internal medicine; Viral load; Reverse-transcriptase inhibitor; Immunology; Logistic regression; Sida; Lentivirus; Human immunodeficiency virus (HIV); Gastroenterology; Pharmacology; Virology; Antiretroviral therapy; Viral disease","authors":[{"name":"Agnes I. Veldkamp","is_ca":false},{"name":"Gerrit Jan Weverling","is_ca":false},{"name":"Joep M. A. Lange","is_ca":false},{"name":"Julio Montaner","is_ca":true},{"name":"Peter Reiss","is_ca":false},{"name":"David A. Cooper","is_ca":false},{"name":"Stefano Vella","is_ca":false},{"name":"David B. Hall","is_ca":false},{"name":"Jos H. Beijnen","is_ca":false},{"name":"Richard M. W. Hoetelmans","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01383608118583745,"gpt":0.2546148819587632,"spread":0.2407788007729257,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006391269,0.0002548435,0.0005119484,0.0004629742,0.00003944761,0.00002062729,0.00009998661,0.0002055072,0.0003422596],"category_scores_gemma":[0.0003841145,0.0001853184,0.00003970088,0.00112333,0.00003789755,0.0001131856,0.00004686997,0.0002544516,0.00009822346],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002387339,"about_ca_system_score_gemma":0.0001281554,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000566983,"about_ca_topic_score_gemma":0.0001785509,"domain_scores_codex":[0.9982114,0.0002664166,0.0003756879,0.00042368,0.0002742148,0.0004485979],"domain_scores_gemma":[0.9991854,0.0001994486,0.00006747103,0.0002784294,0.00005508663,0.0002142073],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00643971,0.001142052,0.9830962,0.000003823282,0.0001266936,0.000945268,0.001769198,0.00001426901,0.003668797,0.00001808858,0.0003906671,0.002385163],"study_design_scores_gemma":[0.0108764,0.006000373,0.9795212,0.000122534,0.00005693285,0.00003361709,0.0001397524,0.00009054182,0.001680113,0.00002804854,0.001213263,0.0002372886],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943609,0.00002420938,0.0000159409,0.004617977,0.00002902812,0.000667267,0.00002123971,0.00009902692,0.0001644629],"genre_scores_gemma":[0.9915957,0.00001397415,0.002755611,0.001099308,0.00002737792,0.0001164979,0.0001804919,0.00002776567,0.00418325],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004858321,"threshold_uncertainty_score":0.7557066,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2887935769","doi":"10.1093/infdis/jiy479","title":"The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; National Institutes of Health; Harvard University Center for AIDS Research; Harvard University; Fred Hutchinson Cancer Research Center; Janssen Pharmaceuticals; Gilead Sciences; Styrelsen för Internationellt Utvecklingssamarbete; Center for AIDS Research, University of Washington; AIDS Healthcare Foundation; GlaxoSmithKline; Canadian Institutes of Health Research; University of Washington; amfAR, The Foundation for AIDS Research","keywords":"Human immunodeficiency virus (HIV); Antiretroviral therapy; Medicine; Antiretroviral drug; Intensive care medicine; Immunology; Viral load","authors":[{"name":"Golnaz Namazi","is_ca":false},{"name":"Jesse Fajnzylber","is_ca":false},{"name":"Evgenia Aga","is_ca":false},{"name":"Ronald J. Bosch","is_ca":false},{"name":"Edward P. Acosta","is_ca":false},{"name":"Radwa Sharaf","is_ca":false},{"name":"Wendy Hartogensis","is_ca":false},{"name":"Jeffrey M. Jacobson","is_ca":false},{"name":"Elizabeth Connick","is_ca":false},{"name":"Paul A. Volberding","is_ca":false},{"name":"Daniel J. Skiest","is_ca":false},{"name":"David M. Margolis","is_ca":false},{"name":"Michael C. Sneller","is_ca":false},{"name":"Susan J. Little","is_ca":false},{"name":"Sara Gianella","is_ca":false},{"name":"Davey M. Smith","is_ca":false},{"name":"Daniel R. Kuritzkes","is_ca":false},{"name":"Roy M. Gulick","is_ca":false},{"name":"John W. Mellors","is_ca":false},{"name":"Vikram Mehraj","is_ca":true},{"name":"Rajesh T. Gandhi","is_ca":false},{"name":"Ronald T. Mitsuyasu","is_ca":false},{"name":"Robert T. Schooley","is_ca":false},{"name":"Keith Henry","is_ca":false},{"name":"Pablo Tebas","is_ca":false},{"name":"Steven G. Deeks","is_ca":false},{"name":"Tae‐Wook Chun","is_ca":false},{"name":"Ann C. Collier","is_ca":false},{"name":"Jean‐Pierre Routy","is_ca":true},{"name":"Frederick Hecht","is_ca":false},{"name":"Bruce D. Walker","is_ca":false},{"name":"Jonathan Z. Li","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01985700599769024,"gpt":0.3328229900501709,"spread":0.3129659840524807,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001112866,0.000204887,0.0006949292,0.00009776819,0.0002657082,0.00002657066,0.0001518736,0.00004522476,0.00005879569],"category_scores_gemma":[0.0009006968,0.0000910707,0.0002973943,0.0001272808,0.0005600268,0.00009424503,0.00004562533,0.0001648114,0.00003795808],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001382149,"about_ca_system_score_gemma":0.0002419858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003839501,"about_ca_topic_score_gemma":0.0001132174,"domain_scores_codex":[0.9974369,0.0006019906,0.00102476,0.0001418594,0.0005947442,0.0001996788],"domain_scores_gemma":[0.9964064,0.00154987,0.0008030812,0.0003561223,0.0007186338,0.0001658436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006275249,0.001996447,0.9737079,0.000009390194,0.007567205,0.00008922997,0.002547701,0.000001526706,0.00005629536,0.00000629921,0.004213034,0.003529696],"study_design_scores_gemma":[0.0232975,0.004934696,0.9591042,0.0002067236,0.006140506,0.0000493495,0.004977457,0.00002815758,0.0001793138,0.0004039592,0.0005522561,0.0001258221],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899055,0.005793321,0.0001051497,0.002572275,0.0007468004,0.0007479875,0.00003103241,0.00002049064,0.00007748799],"genre_scores_gemma":[0.9968406,0.001724669,0.0000111199,0.0002356182,0.0006135774,0.00002914001,0.000005146008,0.00001678669,0.0005233554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01702225,"threshold_uncertainty_score":0.3713756,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135417699","doi":"10.1086/650002","title":"Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials","year":2010,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Raltegravir; Medicine; Antiretroviral therapy; Internal medicine; Integrase inhibitor; Pharmacotherapy; Drug; Human immunodeficiency virus (HIV); Pharmacology; Viral load; Virology","authors":[{"name":"Roy T. Steigbigel","is_ca":false},{"name":"David A. Cooper","is_ca":false},{"name":"Hedy Teppler","is_ca":false},{"name":"Joseph J. Eron","is_ca":false},{"name":"José M. Gatell","is_ca":false},{"name":"Princy Kumar","is_ca":false},{"name":"Jürgen K. Rockstroh","is_ca":false},{"name":"Mauro Schechter","is_ca":false},{"name":"Christine Katlama","is_ca":false},{"name":"Martin Markowitz","is_ca":false},{"name":"Patrick Yéni","is_ca":false},{"name":"Mona Loutfy","is_ca":true},{"name":"Adriano Lazzarin","is_ca":false},{"name":"Jeffrey L. Lennox","is_ca":false},{"name":"Bonaventura Clotet","is_ca":false},{"name":"Jing Zhao","is_ca":false},{"name":"Hong Wan","is_ca":false},{"name":"Rand R. Rhodes","is_ca":false},{"name":"Kim M. Strohmaier","is_ca":false},{"name":"Richard J. O. Barnard","is_ca":false},{"name":"Robin Isaacs","is_ca":false},{"name":"Bach‐Yen Nguyen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03522055684703406,"gpt":0.353666942293186,"spread":0.3184463854461519,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004304123,0.0003123681,0.001219227,0.000113976,0.0001302526,0.00002580251,0.00006063719,0.00009930129,0.00005220312],"category_scores_gemma":[0.0004217776,0.0001536095,0.0001680022,0.0003158531,0.0007536508,0.0001024067,0.00003658287,0.0001790457,7.476923e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004960228,"about_ca_system_score_gemma":0.0002664256,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007724687,"about_ca_topic_score_gemma":0.0002558905,"domain_scores_codex":[0.9975666,0.00035119,0.001168377,0.0004389974,0.000264988,0.0002098595],"domain_scores_gemma":[0.9970734,0.001487422,0.0005983307,0.0004188026,0.0001702045,0.0002519102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06363358,0.01215276,0.9147115,0.00003445629,0.0005748214,0.00001385833,0.0005414441,0.000003690919,0.00004892318,0.00002341554,0.00005717062,0.008204361],"study_design_scores_gemma":[0.1895304,0.006622878,0.8024554,0.0002260657,0.0004795749,0.000002506608,0.00004623527,0.000008492983,0.0003577021,0.00001727049,0.0001054241,0.0001480523],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996853,0.0001373467,0.000008464282,0.0002438061,0.000131747,0.002313975,0.0001105845,0.00003383027,0.0001672623],"genre_scores_gemma":[0.9985492,0.0006739372,0.00008378307,0.00003894959,0.00004358389,0.0001127371,0.0001547035,0.00002130638,0.0003218411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1258968,"threshold_uncertainty_score":0.6264015,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1674196795","doi":"10.1016/s1473-3099(15)00152-8","title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Maple Leaf Medical Clinic","funders":"Janssen Research and Development; ViiV Healthcare","keywords":"Rilpivirine; Efavirenz; Emtricitabine; Regimen; Medicine; Dolutegravir; Nucleoside Reverse Transcriptase Inhibitor; Internal medicine; Raltegravir; Reverse-transcriptase inhibitor; Pharmacology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","authors":[{"name":"David A. Margolis","is_ca":false},{"name":"Cynthia Brinson","is_ca":false},{"name":"Graham Smith","is_ca":true},{"name":"Jerome De Vente","is_ca":false},{"name":"Debbie Hagins","is_ca":false},{"name":"Joseph J. Eron","is_ca":false},{"name":"Sandy Griffith","is_ca":false},{"name":"M H St Clair","is_ca":false},{"name":"Marita Stevens","is_ca":false},{"name":"Peter Williams","is_ca":false},{"name":"Susan L. Ford","is_ca":false},{"name":"Britt Stancil","is_ca":false},{"name":"M Bomar","is_ca":false},{"name":"Krischan J Hudson","is_ca":false},{"name":"Kimberly Y. Smith","is_ca":false},{"name":"William Spreen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01747817052545608,"gpt":0.2684220902275357,"spread":0.2509439197020796,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004724017,0.0006570139,0.00114453,0.0004580253,0.0002449226,0.0001177093,0.0001225031,0.0001581743,0.00004170561],"category_scores_gemma":[0.0001569967,0.0004080364,0.000228073,0.001059027,0.0002846913,0.0005701829,0.0000378631,0.0005983711,0.00005829168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001029602,"about_ca_system_score_gemma":0.0008326743,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002165498,"about_ca_topic_score_gemma":0.001252688,"domain_scores_codex":[0.9968618,0.000400738,0.0005972965,0.0007073217,0.0006995726,0.0007332368],"domain_scores_gemma":[0.9983343,0.0001378144,0.0002949078,0.0006097165,0.0001914895,0.0004317671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6856971,0.002406686,0.2907397,0.0002887204,0.0007325367,0.001588137,0.007485885,0.001082778,0.0001564584,0.00002157647,0.003051442,0.006748923],"study_design_scores_gemma":[0.9433708,0.004476647,0.03904147,0.002285376,0.002371223,0.0004187739,0.00174303,0.000955248,0.0004158323,0.0000711883,0.00375625,0.001094117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924901,0.0005131249,0.000390269,0.0008795336,0.0004813598,0.004005236,0.0001341791,0.0004164054,0.0006898674],"genre_scores_gemma":[0.9960639,0.0002172702,0.0001354601,0.00035563,0.001076612,0.00112397,0.0002838132,0.0000957099,0.00064767],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2576737,"threshold_uncertainty_score":0.9998372,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}